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Abstract.
MODULATION OF GENE EXPRESSION BY TUMOR-DERIVED MUTANT p53.
ROLE OF TRANSACTIVATION IN GAIN-OF-FUNCTION.
By
Mariano J. Scian, Bachelor of Science, EMT-I
Virginia Commonwealth University, Richmond, Virginia.

A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2005.
Director: Sumitra Deb, Ph.D.
Professor, Department of Biochemistry
It was hypothesized that the C-terminal sequences for mutant p53 would be required
for oligomerization, and oligomerization may be critical for gain-of-function. An N
terminal deletion mutant of p53 that deletes amino acids 1 -293 was used as a tool to
perform hetero-oligomerization studies. This mutant retains the entire oligomerization
domain but dispenses off the transactivation domain and a large portion of the sequence
specific DNA-binding domain. Co-transfection experiments show that p53 del. 1 -293
forms hetero-oligomeric complexes with p53-D28 1 G. Also, co-expression of p53 del. 1 293 with p53-D28 1 G inhibited p53-D28 1 G-mediated transactivation of the EGFR and
MDRI promoters suggesting that hetero-oligomerization inactivates transcriptional
functions of mutant p53. The interaction of p53 del. 1 -293 and p53-D28 1 G reduced
transactivation potential of p53-D28 1 G in stably transfected 1 0(3) murine cells.
Therefore, the data presented supports the idea that proper oligomeric forms of mutant
p53 are required for its transactivation function. Expression of mutant p53-D28 1 G also
resulted in increased growth rate (H 1 299 cells), decreased chemosensitivity (H1 299 and
2 1 PT cells) and increased plating efficiency (Saos-2 cells).
Expression of a
transactivation deficient mutant p53 did not induce gain-of-function properties (increased
growth rate and decreased chemosensitivity).
Unlike the other gain-of-function
properties tested, soft agar plating efficiency in Saos-2 cells was not significantly affected
by the expression of a transactivation deficient mutant p53, suggesting that
transactivation may not be the only factor affecting this gain-of-function property. In
order to identify the genes responsible for the observed phenotypes, global gene
expression analyses were carried out using p53-null H 1 299 cell stably transfected to
express mutant p53 (-R 1 75H, -R273H and -D28 1 G). A thorough and stringent analysis
revealed 1 50 genes up-regulated by the expression of mutant p53. Up-regulation of a
number of these genes was confirmed by QPCR and transient transcriptional promoter
analyses; expression of the transactivation deficient mutant p53-D281 G (L22Q/W23S)
did not result in up-regulation of the tested genes further supporting the idea that
transactivation of genes is directly related to gain-of-function phenotypes. Using the
ASNS gene as a model, this transactivation by mutant p53 was concentration dependent
and that the increased transcription did indeed result in increased protein levels.
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H. Chapter 1. Introduction
Structure and function of p53.

The tumor suppressor p53 gene is located on

chromosome 1 7p and encodes an oligomeric, nuclear phosphoprotein that acts as a tumor
suppressor. It is a sequence-specific DNA-binding protein and transcriptional activator
as

well

as

a transcriptional repressor [1 -9].

The consensus DNA-binding site contains

two copies of the 1 0 bp motif 5'-PuPuPuCWWGPyPyPy-3', separated by 0 to 1 3 bp [ 1 0].
(Pu denotes purine base, Py denotes pyrimidine base and W denotes A or T).

All p53

genes from evolutionarily distant species contain five highly conserved regions
designated domains I-V [ 1 1 , 12] (Figure 1).
The sequence-specific DNA-binding domain of p53 is found in the central region
covering the conserved domains II-V (residues 100-293) [13- 1 9].

Additionally, p53

contains a transactivation domain located within residues 1 -73 [20-27], and an
oligomerization domain located within residues 320-360 [ 1 6, 1 9, 23, 28-30]. Sequences
found within the central DNA binding domain are highly evolutionary conserved [ 1 9].
Figure 1 . Structure of WTp53.
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The tumor suppressor p53 has a very short half-life. Levels of p53 in a cell rise after
stress like DNA damage, heat shock, hypoxia or hyperoxia among other stress signals.
Elevated levels of wild-type p53 (WTp53) in response to cellular stress situations lead to
apoptosis or cell cycle arrest [2, 3 1 -4 1 ]. Initial studies on the cell cycle with ionizing
radiation (IR)-exposed cells found that cells expressing a mutated p53 protein failed to
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arrest the cell cycle at the G1/S checkpoint [42].

Subsequently, it was found that

p2 1 1WAF - I , an integral component of this checkpoint, was under the transcriptional
control of p53 [40]. Exposure of cells to IR led to an increase in WTp53 protein levels,
which in turn resulted in elevated levels of p2 1 IWAF-I arresting the cells at the G(/S
checkpoint.

Evidence exists that p53 is involved in a G2/M checkpoint and that loss of

this checkpoint contributes to an increase in polyploid cells [43].
The role of p53 in apoptosis involves the transcriptional up-regulation of Bax, a pro
apoptotic protein [44]. It has also been shown that p53 can down-regulate expression of
the anti-apoptotic protein bcl-2 by interacting with the TATA binding protein to repress
transcription of the gene [44-46].

More recently, a role for p53 has been described at

the mitochondrial level, where p53 is sensitive to the levels of bcl-2 and Bax [47, 48].
More evidence is accumulating describing a role for p53 in DNA excision repair, both as
6
a transcription factor, up-regulating the synthesis of the repair enzyme 0 -alkylguanine
transferase and the p48 subunit of the DNA damage binding protein (DDB2) and as a
component of the nucleotide excision repair (NER) complex by interacting with XPB and
XPD components of the NER-associated TFIIH transcription/repair complex [49-5 1 ].
The p53 protein can also interact with RAD51, topoisomerase-I and topoisomerase-II,
each of which plays a role in recombination, DNA repair and DNA replication [52-55].
All in all, it is evident that p53 is involved in many crucial processes within the cell
(Figure 2).
I;legradation and regulation of p53. As mentioned, elevated levels of WTp53 in

response to cellular stress situations leads to apoptosis or cell cycle arrest [2, 3 1 -4 1 ].
Accumulation of p53 occurs through an increased translation rate and decreased
degradation rate [56, 57].

Under normal circumstances, the levels of p53 are regulated

through its interaction with the mouse double minute 2 protein (MDM2) [58, 59].
MDM2 binds to p53 and maintains relatively low levels of p53 in the cell by
increasing its susceptibility to proteolysis by 26S proteosome and acting as a ubiquitin
ligase [58, 59]. Under stress the MDM2-p53 interaction is blocked and the levels of p53
in the cell rise. It has also been reported that p53-MDM2 complex must be shuttled from
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the nucleus to cytoplasm for p53 to be degraded. [60-63]. Also,during stress human pl4

ARF

is induced and it stabilizes p53 as it inhibits degradation of p53 by MDM2 [64, 65].

Additionally, aside from targeting p53 for degradation, MDM2 can also inhibit p53's
transcriptional activity by physically interacting with the N-terminus of p53 [64,65].
Figure 2. Functions of WTp53.
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The p53 protein also undergoes numerous post-translational modifications during its
activation.

Specific phosphorylation sites have been identified within its amino and

carboxy termini [9, 34, 36, 66-76].

The amino terminal domain undergoes

phosphorylation by various kinases that include, casein kinase, checkpoint kinase 1 and
checkpoint kinase 2, DNA-dependent protein kinase ataxia telangiectasia mutant, jun
kinase and mitogen activated kinase (MAPK) [67,70,74]. The carboxy terminus can be
phosphorylated by various cyclin dependent kinases (CDKs) and protein kinase C (PKC).
Additionally, various acetylation sites have been also identified [67, 70, 74].
Phosphorylation of the N-terminus results in a conformational change that enables
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transcriptional activation of genes, has some effects on DNA binding and results in a
decreased interaction with MDM2 [77].

Changes in the phosphorylation state of the

carboxy terminus have also been shown to affect the conformation of the protein and to
modulate DNA binding activity [78].
Cancer with mutant p53 is more aggressive than cancer without p53. Over 80%

of p53 mutations found in human tumors are missense mutations and in most human
cancers only the mutant protein is expressed [6, 20-22, 79-84].

The percentage of

missense mutations found in the p53 gene is significantly larger than that found for other
tumor suppressor genes [85, 86]. The high frequency of mutation combined with the
apparent selective over-expression of the mutant protein suggests that mutations in the
p53 gene not only destroy the tumor suppressor function of the WT protein, but also that
the mutant protein may gain oncogenic functions. This hypothesis predicts that tumors
expressing mutant p53 may be more aggressive than p53-null tumors and suggests that
patients with tumors expressing a mutant p53 have a poorer prognosis than patients with
tumors lacking p53 altogether. This is true for a number of human cancers [87- 1 06]. For
example, cervical cancers with human papilloma virus (HPV) (which are functionally
p53-null) have a better prognosis than those with mutant p53 (and without HPV) [ 1 1,
1 07- 1 14].
Types of p53 mutations.

While most tumor suppressor genes are inactivated by

mutations leading to an absence of protein synthesis, more than 80% of alterations in the
p53 gene are missense mutations that lead to the synthesis of a stable full-length protein
[18]. In fact more than 50% of human cancers contain a p53 mutation [6, 20-22, 79-84].
Broadly, three types of p53 mutations can be identified [ 1 , 5): 1) loss-of-function,
where the tumor suppressor activities of p53 are abolished; 2) dominant-negative, where
hetero-oligomeric complex formation between wild-type and mutant p53 drives the wild
type p53 into a mutant conformation and results in the inactivation of wild-type p53
present in the cells; and 3) gain-of-function, where mutant p53 attains a dominant
oncogenic role that does not depend on complex formation with wild-type p53.

6

These three categories are based on the following observations: I ) many cancers have
lost wild-type p53 functions [20, 2 1 ] and p53-1- mice are highly prone to tumor
formation, confirming that loss-of-function can result in tumorigenesis; 2) Patients who
inherit the Li-Fraumeni cancer syndrome (LFS) and p53+1- mice develop tumors early
[ 1 1 5]; 3) Many tumors with mutations in the p53 gene retain and over-express the mutant
allele protein implying that mutant proteins perform a vital oncogenic role, and hence are
selectively over-expressed [6, 20-22]. The selective over-expression of mutant p53 is
believed to be required for both dominant-negative and gain-of-function activities [ 1 1 ,
1 8, 1 1 6, 1 1 7].
Walker el al [ 1 1 8] used the IARC database to define 73 "hotspots" for mutations in
the p53 gene. Interestingly, most of these "hotspots" were found at CpG dinucleotides
within exons 5-8 of p53. Six of these CpG "hotspots" were identified within the DNA
binding domain of p53 at residues 1 75, 2 1 3, 245, 248, 273, and 282 [ 1 9]. These residues
are either directly involved in protein-DNA contact (Class I mutants, i.e. R248W and
R273H) or are critically important for maintaining protein structure (Class II mutants, i.e.
RI 75H) [ 1 1 9].
Most naturally arising p53 mutations exhibit an increased stability and accumulate to
high levels yet are unable to function normally and fail to induce the proper response
after cellular stress [ 1 1 9]. Cho el al [ 1 7] showed through X-ray crystallography that in
general mutations of p53 alter the ability of the protein to bind to the promoter regions of
genes under its regulatory control. This presents a convincing explanation for loss-of
function and dominant-negative mutations, which are unable to induce genes such as
p2 1 1W AF-I and Eax that would normally result in cell cycle arrest or apoptosis.
However, it does not explain how mutant p53 can act as a gain-of-function mutation.
Tumor-derived p53 mutants and gain-of-function. As mentioned earlier, WTp53

is a sequence-specific transactivator of genes containing p53-binding sites on their
promoter or transcriptional regulatory sequences [I I ].

Elevated levels of WTp53 in

response to cellular stress situations lead to apoptosis or cell cycle arrest at the Gt or G2
boundaries

by inducing expression of genes that are involved in various aspects of
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cellular growth regulation [2, 3 1 -41). Tumor-derived p53 mutants are defective in these
functions (Ioss-of-function).
The high frequency of missense mutation (as opposed to deletions or truncations)
distinguishes p53 from other tumor suppressors and suggests that there is a selective
pressure for mutant p53. Indeed, expression of mutant p53 in cells devoid of endogenous
WTp53 has been shown to induce various growth promoting and proliferative functions
[1 1 , 1 20- 1 30). These activities are not shared with wild-type p53.
One of the most important discoveries with regard to mutant p53 gain-of-function
was the ability of the mutant protein to enhance the tumorigenicity of cells lacking
expression of p53 [1 1 , 129-1 32].

Through the years, various activities have been

attributed to mutant p53, which include (I ) increased tumorigenicity [ 1 33, 1 34], (2)
increased metastasis and tissue invasiveness [ 1 35], (3) increased growth in soft agar
[136], (4) decreased sensitivity against chemotherapeutic drugs [ 1 37, 1 38], (5) increased
resistance to y-irradiation [ 1 39], (6) accelerated chemical carcinogenesis [ 1 40], (7)
increased homologous recombination induced by ionizing radiation [ 1 40], (8) disruption
of spindle check point [ 1 24], (9) activated topoisomerase I activity [ 1 41], (10) increased
growth rate [ 1 42] and (1 1 ) induction of gene amplification [1 43). Many of the gain-of
function data come from p53-null systems (eliminating the possibility of dominant
negative effects) where the expressed mutant p53 level was comparable to that observed
in cancer cells [ 1 29).

This suggests the strong possibility that mutant p53 gain-of

function has a true physiological role, which may lead to aggressive cancer development
and poorer prognosis.
Most of the gain-of-function properties have been demonstrated using p53-null cell
culture systems.

This is not an ideal system, since cells may accumulate further

mutations while in culture, making the system an inaccurate representation of human
tumors. To this end, mouse models have been generated in order to further understand
the role of mutant p53 in oncogenesis. It has been observed that p53-null mice develop
early onset lymphomas making long term studies of gain-of-function in these mice a bit
complicated [ 1 44). Using a knock-in mouse line, Liu et af. [1 45, 146] showed increased
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metastatic potential in mice inheriting p53-RI 72H (a murine p53 mutant homologous to
the human p53-RI 75H). Using a murine p53-RI 72H mutant transgenic model system
Wang et a/. [ 1 24, 1 40] showed some evidence of gain-of-function associated with
genomic instability and Murphy et a/. [ 1 42] reached similar conclusions using the same
p53 mutant in a mammary epithelial murine cell model. Hixon et al. [ 1 47] proposed that
cells carrying mutant p53 over-express CksI , a protein that mediates activating
phosphorylation of the anaphase promoting complex (APC) by cdc2 leading to
chromosomal instability as cells are unable to sustain APC inactivation. More recently,
clear and strong evidence of mutant p53 gain-of-function has been demonstrated in two
mouse models of the Li-Fraumeni Syndrome where higher metastatic spread and/or
different tumor spectrum have been observed in the presence of mutant p53 [ 1 48, 149].
Mechanisms of mutant p53-mediated gain-of-function. Mutant p53 may achieve

gain-of-function phenotypes by a direct acquisition of new functions actively involved in
proliferation processes [ 1 1 9]. Two possible models have been proposed to explain the
molecular mechanism underlying mutant p53 gain-of-function.
The first, involves transcriptional modulation by mutant p53 of specific target genes.
For example, mutant p53 may transactivate growth promoting genes, disrupt DNA repair
or apoptotic activities or even inhibit growth suppressive genes [ 1 50- 1 52]. It has been
shown that mutant p53 can transactivate promoters of growth-related genes in vivo, even
in the absence of WTp53, such as human proliferating cell nuclear antigen (PCNA),
epidermal growth factor receptor (EGFR), interleukin 6 (IL-6), multiple drug resistance I
(MDRl), basic fibroblast growth factor (BFGF) and

c-myc

among others [reviewed in

[85, 1 19], [1 1 , 120, 134, 1 53-155]]. The sequence requirements for mutant p53-mediated
transactivation of these genes is independent of a p53 DNA binding consensus and it is
believe that mutant p53-mediated regulation of these promoters is through its interaction
with other factors. Structure-function analyses indicate that the d9main requirements for
transactivation by WT and mutant p53 are different and that mutant p53 does not require
a WTp53 DNA binding site [133, 134, 1 55, 1 56].

It is recognized that mutant p53

requires both its amino and carboxy termini for gain-of-function [ 1 33, 134].

A
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transactivation deficient fonn of mutant p53-D28 1 G that incorporates two additional
mutations within the transactivation domain [p53-D28 1 G (L22Q/W23S)] that disrupt
TAF interactions and c-tenninal modifications can no longer transactivate the MDR 1 and
c-myc

promoters [ 1 33, 1 54].

More importantly, this transactivation deficient mutant

failed to confer tumorigenic potential in p53-null fibroblasts [ 1 33]. Taken as a whole,
modulation of gene expression by mutant p53 in oncogenesis remains largely
uninvestigated (Figure 3).
Figure 3. Differences between mutant and WTp53.
WTp53
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The second model explaining mutant p53-gain-of-function involves protein-protein
interactions between mutant p53 and other cellular protein(s) such as the p53 family
members, p73 and p63, DNA repair machinery proteins, and/or proteins of the apoptotic
pathway in the cytoplasm and/or mitochondria [ 1 57, 1 58]. The proteins p73 and p63
have structural and functional similarity with p53, and have been shown to transactivate
promoters containing p53-binding sites [ 1 59- 1 62]. Like WTp53, p73 can also induce
apoptosis or growth suppression of cells expressing elevated levels of the protein [ 1 591 62]. Over-expression of p73 in different cancer cell lines has been detected, providing
evidence that p73 may substitute for WTp53 as a tumor suppressor in cells lacking
expression of p53 altogether [ 1 63, 1 64]. Tumor-derived mutant p53 may inactivate the
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physiological functions of p73 (or p63) through hetero-oligomerization. Evidence of this
phenomena exists in the literature ( 1 59, 1 60]. It is possible then that at least part of the
oncogenic effect of mutant p53 arises from an interaction of the mutant protein with
endogenous p73 (or p63).

This interaction, however, is affected by a common p53

polymorphism at residue 72 (R vs. P) where a R72 form is more likely to interact with
p73/p63 than the P72 form of p53 [ 1 65, 1 66].

Using isogenic cell lines expressing

various p53 mutants in their R 72 or P72 form, Bergamaschi et al. ( 1 67] showed that
those mutants expressing the R72 form were more resistant to chemotherapy.
Interestingly, the mutant background used in this study is P72.
The gain-of-function properties of mutant p53 may also be dependent on protein
protein interactions other than p53/p76-p63 interactions. A number of proteins have been
identified that specifically interact with either WT or mutant p53 ( 1 1 9]. Mutant p53
binding protein I or MBPI , an oncogenic protein, has been found to interact with p53RI75H and other p53 mutants but not with WTp53 [ 1 68]. There is also evidence to
indicate that mutant p53 may promote homologous recombination [53; 1 4 1 ]. WT and
mutant p53 also interact differently with MDM2 ( 1 69]. Interestingly, the central DNA
binding domain of mutant p53 and not of WTp53, binds to MDM2. It is not clear,
however, whether this interaction has any impact on gain-of-function.
Although major emphasis has been given on the transcriptional function of WTp53,
functions independent of transcription have also been described [ 1 70- 1 74]. For example,
Mihara et al. ( 1 58] demonstrated a direct apoptogenic role of WTp53 at the
mitochondria, independent of its transcriptional activity. Chipuk et al. ( 1 70] also showed
a transcription-independent apoptotic role of WTp53 that may initiate in the cytoplasm.
The impact of mutant p53 on these processes, if any, is unknown. Ohiro et al. [ 1 75]
showed that mutant p53 inhibits stress-inducible kinase pathways, and demonstrated its
anti-apoptotic activity. This activity was also independent of the transactivation function
of mutant p53.
The two proposed models are not mutually exclusive and the most likely scenario is
that mutant p53 disrupts cellular functions by both transcription-dependent and -

II

independent mechanisms.

Future proteomic analysis in conjunction with functional

assays will lead to a clarification of the role of protein-protein interactions in gain-of
function.
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I. Chapter 2. Hypothesis

a. Major hypothesis.

The major hypothesis of this work was: Mutant p53 up-regulates specific genes
leading to gain-of-function properties and oncogenicity of cells expressing mutant p53.
This up-regulation of genes is transactivation dependent contributes to gain-of-function
properties of mutant p53.
This hypothesis was based on the following observations. Experiments with WTp53
in which the tetramerization domain had been replaced by a heterologous dimerization or
tetramerization domain have shown that the heterologous oligomerization domain
preserves wild-type p53-mediated transactivation and growth suppression (including GIIS
inhibition) functions [ 1 76- 1 80]. However, no information was available regarding the
consequences of replacing the oligomerization domain of tumor-derived p53 mutants.
Using murine non-tumorigenic p53-null 1 0(3) cells, it had been shown that expression of
tumor-derived p53 mutants such as p53-D28 1 G, -R 1 75H and -R273H increase the
tumorigenicity of the cells in nude mice remarkably [ 1 33, 1 34]. Further experiments
demonstrated that the transactivation function of p53 mutants was required for its
oncogenic function [ 1 33, 1 34].

Blandino et af. [ 1 28], reported that mutant p53

expression (in cells devoid of WTp53) can lead to decreased sensitivity against
chemotherapeutic drugs such as doxorubicin, etoposide, cisplatin. Other groups have
reported similar results [ 1 26, 1 37, 1 38, 1 8 1 - 1 86].

Several other gain-of-function

phenotypes have been reported [ 1 33- 1 43], yet, the exact role of transactivation, if any,
had not examined in detail.

Finally, evidence in the literature suggested that

transactivation played a role in mutant p53 tumorigenicity. As such, it was important to
identify target genes modulated by mutant p53 in the absence of WTp53.

It was

hypothesized that this type of analysis would reveal a set of target genes whose
transcriptional modulation by mutant p53 would explain the gain-of-function phenotypes
observed.
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b . Specific Aims.

The following are the specific aims: ( 1 ) To determine whether the oligomerization
domain and C-terminally located sequences are necessary for transactivation and gain-of
function properties of mutant p53; (2) To determine whether mutant p53 requires its
transactivation function to induce gain-of-function properties; and (3) To identify genes
modulated by tumor-derived p53 mutants.
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J.

Chapter 3.
Hetero-oligomerization does not Compromise Mutant p53
Gain-of-Function.

The work presented in this chapter has been published in the Oncogene research journal (Oncogene.
2002 Jan 1 0;21 (2): 176-89.). CAT assays and 35S immunoprecipitations were performed by D Deb, QPCRs
by KE Roth and colony forming and tumorigenicity assays by AS Chakraborti.

a. Introduction.

Replacement of the oligomerization domain of WTp53 with a heterologous
dimerization or tetramerlzation domain showed that it could preserve WTp53-mediated
transactivation and growth suppression functions [ 1 76, 1 77, 1 79, 180, 1 87].

Similar'

experiments showed that the gain-of-function phenotype of tumor-derived p53 mutants
also required the C-terminally located oligomerization/nucleic acid-binding domain
[ 1 34]. However, no information was available regarding the consequences of replacing
the oligomerization domain of tumor-derived p53 mutants and whether the C-terminal
regions are only required for oligomerization or have other function(s) necessary for
mutant p53-mediated transactivation and/or gain-of-function.

b. Experimental Results.
Replacement of the tetramerization domain inhibits mutant p53-mediated
transactivation.

Earlier, this laboratory had shown that several tumor-derived p53

mutants could transactivate promoters of a number of growth-related genes including the
EGFR gene promoter [153, 1 55]. However, the deletion mutant p53-D28 1 G del. 393327, which eliminates the oligomerization domain of the protein, failed to transactivate
the promoter [ 1 55], suggesting that proper oligomerization of a tumor-derived p53
mutant is required for the transactivation function of the mutant protein.
Therefore

it

was

necessary

to

determine

if

the

C-terminally

located

oligomerization/non-sequence-specific nucleic acid binding domain is required only for
oligomerization. It was shown earlier that replacement of the tetramerization domain of
WTp53 by a ditnerization domain consisting of the coiled-coil structure from the yeast
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GCN4 protein (or a derivative of the coiled-coil structure that results in a tetramerization
domain) could effectively sustain wild-type p53-transactivation and growth suppression
functions [1 76, 1 80, 1 87]. Performing similar experiments, p53-D281G derivatives with
such a replacement of the tetramerization domain would be predicted to retain the
transactivation function.
The effect of expression of p53-D28 1 G, p53-D28 1 G 343cc (the coiled-coil structure
from GCN4 is placed after the amino acid 343) [ 1 78] and p53-D28 1 G TZ334NR (a
modified GCN4 coiled-coil structure is placed after amino acid 334 such that it functions
as a tetramerization domain) [ 1 80] on the activity of the EGFR promoter was studied
(Figure 4). Transfections were carried out in p53-null Saos-2 cells.
The results shown in Figure 5 from luciferase assays demonstrate that p53-D28 1 G
mediated transactivation of the EGFR promoter is not preserved by replacing its
This

tetramerization domain by a heterologous dimerizationltetramerization motif.

suggests that this region performs some vital function(s) required for mutant p53mediated

transactivation that cannot

simply be substituted by a heterologous

dimerizationltetramerization domain. Amino acid residues 320-360 of p53 code for the
tetramerization domain [ 1 6, 23, 28, 1 88].

Besides partial substitution of this domain

(starting from residue 334), the C-terminal amino acids past the oligomerization in p53D28 1 G TZ334NR have been deleted (residues 352-393). This segment may also play an
important role in mutant p53-mediated transactivation.
Figure 4. Schematic representation of p53-D281 G oligomerization derivatives.
320

p53-D28IG
p53-D281G lZ334NR
p53-D28I G 1Z334NR 1352
p53-D28I G 343cc

p53-D28IG del 393-327

02810

393

334

02810

334

393

02810
02810
327
02810
294

p53 del. 1 -293

360

393
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The mutant p53-D28 1 G TZ334NRI352, having the sequences 352-393 inserted
following the TZ moiety was also tested. This mutant transactivated the best among all
the domain replacement mutants. The western blot analysis shows equivalent amounts of
expression by p53-D28I G and p53-D28 1 G TZ334NR, thus an expression deficiency
cannot explain the inability of p53-D28 1 G TZ334NR to transactivate. The experimental
results suggest that the C-terminally located amino acids 352-393 perform a vital function
for mutant p53-mediated transactivation since transactivation by this mutant was 4 fold
over that of p53-D28 1 G TZ334NR. Earlier, a similar conclusion was reached by Frazier

et a/. [ 1 54], demonstrating a requirement for amino acids 370-380 for transactivation of
the c-myc promoter by p53-D28I G. Similar experiments were carried out using WTp53
(data not shown). Replacement of the oligomerization domain of WTp53 did not affect
the transactivation ability of the protein in agreement with earlier studies (data not
shown) [ 1 76, 1 77, 1 79, 1 80, 1 87].
Figure 5. Replacement of the tetramerization domain of mutant p53 has a drastic
effect on mutant p53-mediated transactivation.
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could be a defect in oligomerization. Using a glutaraldehyde cross-linking assay, the
ability of the mutant p53 to form tetramers was tested as described [23]. The various
mutant p53 forms were synthesized using 35 S-labeled methionine and an in vitro
transcription-translation

system.

The

synthetic

proteins

were

incubated

with

glutaraldehyde at varying final concentrations (Figure 6). After cross-linking,the protein
oligomers were analyzed using a gradient (4-20%) sodium dodecyl sulfate (SDS)
polyacrylamide gel electrophoresis (SDS-PAGE).
Figure 6. Replacement of the tetramerization domain of mutant p53 preserves
tetramerization of the protein.
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The data shown in Figure 6 indicates that p53-D28 1 G, p53-D28 1 G TZ334NR1352
and p53-D281G TZ334NR oligomerized, while p53-D281G del 393-327 could not,
although there is some variation in tetramerization among p53-D28 1 G, p53-D28 1 G
TZ334NR1352 and p53-D28 1 G TZ334NR. Since p53-D28 1 G TZ334NR1352 and p53D28 1 G TZ334NR are capable of oligomerization into tetramers, the results shown in
Figure 4 demonstrate that the C-terminally located oligomerization/nucleic acid binding
domain is required for p53-D28 1 G-mediated transactivation.
Transactivation of the EGFR and MDRI promoters by the tumor-derived
mutant p53-D281 G is inhibited by co-expression of p53 del. 1 -293.

oligomerization

of

WTp53

with

miniproteins

containing

only

the

Hetero
C-terminal

oligomerization domain results in inactivation of WTp53 function ( 1 89]. Therefore, it
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was also necessary to investigate if such an interaction would inactivate mutant p53
mediated transactivation.

Saos-2 cells were co-transfected with EGFR.Luc [ 1 55] or

MDR l . CAT (chloramphenicol acetyl transferase) [ 1 33, 1 90], an expression plasmid for
p53-D28 1 G (or vector alone) and an expression plasmid for p53 del. 1 -293 (or vector
alone).
Figure 7. Transactivation of the EGFR promoter by tumor-derived mutant p53D28 1 G is inhibited by co-expression of p53 del. 1 -293.
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Transfections, CAT and luciferase assays were carried out as described in Materials
and methods. Figures 7 and 8 show the results of the assays; it is apparent that although

19

the tumor-derived p53-mutant transactivated the EGFR and MDRI promoters, this
transactivation was significantly reduced by the co-expression of p53 del. 1 -293.
Western blot analyses examining expression of the two proteins from a representative
experiment demonstrates that the proteins were adequately expressed; thus, lack of
transactivation by p53-D28 1 G in the presence of p53 del. 1 -293 cannot be explained by
protein expression deficiencies. It is possible then that hetero-oligomers between p53D281 G and p53 del. 1 -293 are inactive in transactivation.
p53 del. 1-293 complexes with p53-D28 1 G in vivo. Since co-expression of p53 del.

1 -293 reduced mutant p53-D281 G transactivation it was necessary to check whether
these two proteins interacted in vivo. Saos-2 cells were co-transfected with expression
plasmids for p53-D28 1 G (or vector alone) and p53 del. 1 -293 (or vector alone) into Saos2 cells. Twenty-four hours after transfection, cells were labeled in vivo by

3

5

S_

methionine. Cell extracts were prepared and used in immunoprecipitations (Figure 9).
Immunoprecipitations were perfonned using an antibody specific for the N-tenninus
of mutant p53 (Ab DO l , Figure 9).

Western blot analysis was conducted using an

antibody against the C-tenninus of p53.

Although the antibody DOl could not

immunoprecipitate p53 del. 1 -293 alone (Figure 9, lane 4), it could precipitate the
deletion mutant in the presence of p53-D28 1 G (Figure 9, lane 3). This shows that p53
del. 1 -293 binds with p53-D28 1 G in vivo fonning a hetero-oligomeric complex. Thus,
results of these experiments (Figures 6-8) suggest that proper oligomeric fonns of p53D28 1 G are necessary for its transactivation function.
Figure 9. The protein p53 del. 1 -293 co-immunoprecipitates with p53-D28 1 G.
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Co-expression of p53 del. 1-293 inhibits the endogenous transactivation by p53D28 1 G. Hetero-oligomerization of wild-type p53 with tumor-derived p53 mutants (or

polypeptides covering the oligomerization domain of p53) inhibits wild-type p53
biological functions leading to immortalization and transformation of rat embryo
fibroblasts [ 1 89]. Since co-expression of p53 del. 1 -293 and p53 (wild-type or mutant)
inhibited

p53

transactivation

[ 1 9 1 ],

it was important to test whether hetero

oligomerization between p53-D2 8 1 G and p53 del. 1 -293 would lead to inhibition of
transactivation of endogenous genes by p53-D28I G.
To identify genes endogenously transactivated by p53-D28 1 G, p53-null murine 1 0(3)
cells stably transfected with p53-D28 1 G were compared with cells stably transfected with
vector (pCMVBarnNeo, Hinds e/ al., 1 990) alone by microarray hybridization analysis
(lncyte Genomics). The analysis identified a number of genes expressed at a higher level
in p53-D2 8 1 G expressing cells with a fold difference in expression of two or more. Two
such genes, PCNA and NF-KB2, were chosen to see the effect of co-expression of p53
del. 1 -293 . Quantitative real time PCR (QPCR) analysis of cDNA made from total RNA
shows that the levels of both the genes are considerably higher in 1 0(3) cells expressing
the mutant p53-D28 1 G compared to that in cells stably transfected with vector alone
(Figure 1 0).
Figure 1 0. Co-expression ofp53 del. 1 -293 inhibits transactivation by p53-D28 1 G.
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Furthermore, co-expression o f p53 del. 1 -293 decreased the level of the RNAs to
some extent suggesting that hetero-oligomerization indeed inhibits transactivation by
mutant p53. Interestingly, 1 0(3) cells expressing p53 del. 1 -293 expressed more of the
two RNAs compared to vector-transfected cells. A possible explanation for these results
may be that mutant p53 transactivates these genes through a synergistic interaction with
another transactivation factor after localization of the complex on or near regulatory
regions of the genes. Since p53 del. 1 -293 does not posses a transactivation domain, the
observed up-regulation may be due to that second transactivating protein.

This

possibility also suggests that the interacting factor binds/interacts with mutant p53 at its
C-terminus.
p53 del. 1-293 did not inhibit colony formation by p53-D28 1G. Expression of

p53-02 8 1 G also gives growth advantage to cells expressing the mutant protein [ I I ] . It
was therefore necessary to determine whether p53 del. 1 -293 expression could influence
the growth advantage conferred by mutant p53 . Using a colony formation assay to assay
for cell proliferation, 1 0(3) cells stably expressing the expression vector (pCMYBam
NEO) alone or expression plasmid for p53-028 1 G were transfected with the following
expression plasmids: ( I ) pCMYBam and pHyg, (2) pCMYBam p53 (wild-type) and
pHyg, (3) pCMYBam FLAG-p73a and pHyg, (4) pCMYBam p53 del. 1 -293 and pHyg.
The data presented in Table 1 indicates p53-02 8 1 G expressing cells have a discernable
growth advantage over vector-transfected cells. The deletion mutant p53 del. 1 -293 had
little effect, if any (compared to vector alone), on the growth properties of p53-028 1 G
expressing cells. Co-transfection of the cells with WTp53 or p73a decreased the number
of colonies formed substantially, as expected, since both WTp53 and p73a have been
shown to be growth inhibitors when expressed in cells [2, 3 1 -4 1 , 1 92]. Thus, once again
we find that del. 1 -293 could not significantly change the growth enhancing function of
mutant p53 suggesting that hetero-oligomerization may not be enough to inhibit gain-of
function.
In an earlier report, it was shown that a deletion of the C-terminal sequences of p53028 1 G overlapping the oligomerization domain disrupts gain-of-function properties.
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Here experimental data suggest that hetero-oligomerization disables transactivation by
p53-D28 l G without eliminating gain-of-function properties (tumorigenicity).

Taken

together this information suggests that the C-terminal sequences have a separate role in
gain-of-function in addition to that in transactivation.
Table 1. Colony formation in 1 0(3) cells.
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Vector alone, clone 4

pHyg and pCMYBam

p53-D28IG, clone 4

pHyg and pCMYBam

1 37, 1 1 7, 132; avg. 1 29

Vector alone, clone 4

pHyg and pCMYBam WTp53

4,0,0; avg. 1 .33

p53-D28 I G, clone 4

pHyg and pCMVBam WTp53

4,2 1 ,5 ; avg. 1 0

Vector alone, clone 4

pHyg and pCMYBam p73a

3,8,38; avg. 1 6.33
0,8, 1 8 ; avg. 8.67

0,0,2; avg. 0.67

p53-D28IG, clone 4

pHyg and pCMYBam p73a

Vector alone, clone 4

pHyg and pCMYBam p53 del. 1 -293

1 ,4,0; avg. 1 .67

p53-D28I G, clone 4

pHyg and pCMYBam p53 del. 1 -293

1 1 3,1 25,107; avg. 1 1 5

Co-expression of p53 del. 1-293 does not inhibit tumorigenicity of 10(3) cells
expressing the mutant p53-D281G protein. It was important to test whether hetero

oligomerization between p53 del. 1 -293 and p53-D28 1 G would lead to inhibition of
tumorigenicity of mutant p53 expressing cells.

Although 1 0(3) cells expressing p53-

D28 1 G form tumors, cells stably expressing p53-D28 1 G del. 393-327 (defective in
oligomerization) do not [ 1 34].

This suggested a role for oligomerization in gain-of

function.
Stable cell lines were generated from 1 0(3) cells (I ) expressing p53-D28 1 G, (2)
expressing p53 del. 1 -293, (3) expressing p53-D28 1 G and p53 del. 1 -293 and (4) stably
transfected with vector alone [ 1 0(3) V4]. Cells were checked for expression by western
blot analysis (data not shown). Two different clones from each stable transfection were
inj ected subcutaneously into two or three different nude mice (two sites on each mouse)
as

described in Materials and methods. The mice were then observed for several weeks

for appearance of tumors.
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As shown in Table 2, 1 0(3) cells stably transfected with pCMVBam vector alone or
stably expressing p53 del. 1 -293 did not show any tumor formation even after five
months. In cells expressing p53-D28 1 G and p53 del. 1 -293 tumors appeared within 1 -2
weeks of injection; a similar situation was observed with 1 0(3.) cells expressing p53D28 1 G alone.

Since co-expression of p53 del. 1 -293 and p53-D2 8 1 G did not reduce

tumorigenicity, hetero-oligomerization may not interfere with mutant p53-mediated
tumorigenesis.
Table 2. Twnorigenicity of 1 0(3) cells expressing p53 derivatives.

Vector alone, clone 2

2/4

0/4

Vector alone, clone 2 1

2/4

0/4

p53 del. 1-293, clone 1 7

2/4

0/4

p53 del. 1-293, clone 1 9

3/6

0/6

p53-D281 G, clone 13

3/6

6/6

p53-D281 G, clone 4

2/4

4/4

3/6

6/6

3/6

6/6

p53-D281 G, clone 4 and
p53 del. 1 -293 cloDe 22
p53-D28 1 G, clone 4 and
p53 del. 1 -293, clone 1 0

Hetero-oligomers are produced between p53-D28 1 G and p53 del. 1-293 i n 1 0(3)
cells.

Since co-expression of p53-D28 1 G and p53 del. 1 -293 in 1 0(3) cells did not

interfere with tumorigenicity, in vivo complex formation between these two proteins
needed to be confUTned.

Extracts from 1 0(3) cells expressing the p53 del. 1 -293

deletion mutant alone and cells expressing p53-D28 1 G and p53 del. 1 -293 were prepared
and immunoprecipitation reactions carried out as described in Materials and methods.
lmmunoprecipitations were performed with the antibody DO I . The immunoprecipitates
were separated by SDS-PAGE, and proteins transferred to a nitrocellulose membrane.
The blot was then developed with PAb42 1 antibody. The data shown in Figure I I show
that DO l immunoprecipitates both p53-D28 1 G and p53 del. 1 -293 indicating that hetero-
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oligomer formation between the two proteins occurs.

As expected, DO 1 did not

immunoprecipitate p53 del. 1 -293.
Figure 1 1 . Hetero-oligomers are produced between p53-D2 8 1 G and p53 del. 1 -293 in
1 0(3) cells stably expressing the two proteins.
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c. Chapter Summary.

It was hypothesized that the C-terminal sequences for mutant p53 would be required
for oligomerization, and oligomerization may be critical for gain-of-function.

An

N

terminal deletion mutant of p53 that deletes amino acids 1 -293 was used as a tool to
perform hetero-oligomerization studies. This mutant retains the entire oligomerization
domain but dispenses of the transactivation domain and a large portion of the sequencespecific

DNA-binding

domain.

Co-transfection

experiments

followed

by

immunoprecipitation showed that p53 del. 1 -293 forms hetero-oligomeric complexes
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with p53-D28 1 G. Also, co-expression of p53 del. 1 -293 inhibited p53-D28 1 G-mediated
transactivation

of the

EGFR

and

MDRI

promoters

suggesting

that

hetero

oligomerization inactivates transcriptional functions of mutant p53 . The interaction of
p53 del. 1 -293 and p53-D28 1 G reduced transactivation potential of p53-D28 1 G in stably
transfected 1 0(3) murine cells. Although 1 0(3) cells stably transfected with p53-D28 1 G
expressed 5-6-fold more peNA and NF-KB2 mRNA compared to the cells transfected
with vector alone, co-expression of p53

considerably.

del.

1 -293 reduced this up-regulation

Therefore, the data presented supports the idea that proper oligomeric

forms of mutant p53 are required for its transactivation function. The transactivation data
generated supports this idea, yet tumorigenicity and colony formation assays show that
co-expression of the deletion mutant in the presence of p53-D2 8 1 G does not inhibit gain
of-function by mutant p53 . Thus, hetero-oligomerization between p53-D2 8 1 G and p53
del. 1 -293 may not completely inhibit p53-D28 1 G growth enhancing properties, although
it does inhibit its transactivation ability.
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Chapter 4.

Role of Transactivation in Mutant p53 Gain-of-Function Properties.
The work presented in this chapter has been published in the journals Oncogene and Cancer Research
(Oncogene. 2002 Jan 1 0;2 1 (2): 176-89. and Cancer Res. 2004 Oct 1 5 ;64(20):7447-54).

a. Introduction.

Using murine non-tumorigenic p53-null 1 0(3) cells it had been shown that expression
of tumor-derived p53 mutants such as p53-D2 8 1 G, -R1 75H and -R273H increase the
tumorigenicity of the cells in nude mice remarkably [ 1 33, 1 34].

Further experiments

demonstrated that the transactivation function of p53 mutants was required for its
oncogenic function [ 1 33 , 1 34].
Blandino et at. [ 1 26, 1 28, 1 3 7, 1 3 8, 1 8 1 - 1 86], reported that mutant p53 expression (in
cells devoid of WTp53) can lead to decreased sensitivity to chemotherapeutic drugs such
as doxorubicin, etoposide, cisplatin and other groups have also reported similar results
[ 1 26, 1 28, 1 37, 1 3 8, 1 8 1 - 1 86]. Several other mutant p53 gain-of-function phenotypes
have been described in the literature [ 1 3 3- 1 43], yet the exact role of transactivation, if
any, was not examined. Here, the role of transactivation was examined in three gain-of
function phenotypes (growth rate, chemosensitivity and soft agar plating efficiency).

b. Experimental results.
Expression of tumor-derived mutant p53 in p53-null cells confers a grow th
advantage. In order to explore the role of mutant p53 mediated transactivation in the

various gain-of-function phenotypes it was first necessary to detennine if the p53 mutants
available in the laboratory could induce any gain-of-function. A series of p53 mutants
found in human cancers were selected for the initial studies. For example, mutations at
amino acid 1 75 account for 5.09% of all p53 mutations found in human cancers and
mutations at 273 for 6.49% I . Using the colony assay described [ 1 56] we co-transfected
http://p53. curie.frI). Percentages are calculated with respect
I Data has been adaptedfrom p53 Database (
to the total p53 mutations reported/or all human cancers.

27

1 0(3) cells with pCMV-Bam Neo and pCMV-Bam p53 (WT or mutant) or pCMV-Bam
expression vector. Forty-eight hours after transfection the cells were subcultured and
grown in selective media with periodic changes in media every three or four days. After
three to four weeks of selection the cells were stained and colonies were counted. If p53
confers growth advantage and aids in transformation in 1 0(3) cells they should multiply
faster than the vector transfected cells leading to an increased number of neomycin
resistant colonies.
Co-expression of WTp53 with the pCMV -Bam Neo vector, as expected, reduced the
number of colonies formed when compared to vector transfected cells (Figure 1 2). In
contrast, cells transfected with mutant p53 showed an increased number of colonies
formed, ranging from no change at all (i.e. p5 3-HI 79Y) to two- (i.e. p53-R I 75H) or
three- (i.e. p53-D28 1 G) fold increase, indicating that expression of most of the p53
mutants confers a growth advantage on the cells. Mutant p53-D28 1 G formed the highest
number of colonies compared to any of the other p53 mutants examined.
Figure 12. Expression of tumor-derived mutant p53 increases the formation of
neomycin resistant colonies.
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Tumor-derived p53 mutants do not bind the p53 consensus site. WTp53 function

is largely dependent on the ability of the protein to bind DNA and act as a transcriptional
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activator. It can bind to a consensus sequence that contains two copies of a 10 base pair
motif 5 '-PuPuPuCWWGPyPyPy-3' separated by O- 1 3bp ( 1 93 ] . Consequently, mutations
in the DNA-binding domain of the WT protein would result in the inability of the mutant
protein to bind DNA.
Figure 13. DNA binding of WT and tumor-derived p53 mutants.
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Electrophoretic mobility shift assays (EMSAs) were performed to study the ability of
our p53 mutants to bind a p53 DNA-binding site. Assays were conducted using a probe
containing the distal p53-binding site found in the p2 1 promoter to determine the ability
of the p53 mutant to bind the WTp53 DNA consensus site [ 1 94] (Figure 1 3).
Lanes 1 -5 were incubated with purified protein ( l OOng) [ 1 95] while lanes 6-23 were
incubated with 1 0 Ilg of total protein from nuclear extracts generated after transfection of
SAOS-2 cells with expression plasmids for the specified p53 protein.

As expected

WTp53 can bind the probe (lanes I , 6-7) containing the p53-binding site (p2 1 WT). The
same probe added in excess as a cold competitor (lanes 2-3, 8-9) diminishes the amount
of protein binding observed, and a non-specific competitor (P2 1 MT) added in excess has
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no effect in the binding (lanes 4-5, 1 0- 1 1 ). Addition of a p53 specific antibody (DO 1 )
produces a supershift (lane 1 2). Under the same conditions, any of the twelve mutant p53
species tested were unable to bind the binding site containing probe (lanes 1 4-23).
Similar results were obtained using a probe containing the consensus p53 sequence found
in the Ribosomal Gene Cluster promoter (data not shown).
Figure 14. Transcriptional activation of p53 -inducible promoters by mutant p53 .
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Since mutations in the p53-DNA binding domain can effectively obliterate DNA
binding ability of the mutant p53 under the conditions of this assay, the question remains
as

to how some tumor-derived p53 mutants are capable of transactivating genes such as
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MDR I , PCNA and

c-myc,

all of which are inhibited in the presence of WTpS 3 . These

facts present the possibility that the transactivation observed is mediated through the
actions of another transcription (or DNA binding) factor such as Spl or through direct
binding of the mutant protein to a site of as yet unknown sequence.
Mutant p53 does not transactivate or repress WTp53-regulated promoters. The

tumor suppressor function of the pS3 protein is correlated with its ability to
transcriptionally activate or repress gene expression [ I , 2, 34].

Promoter assays were

performed to examine the ability of the various tumor-derived pS3 mutants to
transactivate targets of WTpS3 (i.e. p2 1 and MDM2). WTpS3 induced the p2 1 promoter
by approximately 1 2-fold compared to the vector. The same amount of tumor-derived
pS3 mutants was unable to elicit a response of such magnitude (Figure 1 4). Five of our
mutants,

pS3-V I 43A,

pS3-V I S7F,

pS3-Y I 63C,

pS3-D28 I G,

and

pS3-R282W

transactivated this promoter by at least 2-fold, suggesting that some mutants may have
some residual WTpS3 activity or can transactivate this promoter using a different
molecular mechanism.
The effects of the pS3 mutants on the promoter of the human mouse double minute 2
(MDM2) gene, another target of WTpS3 was also examined [34, 3S, 76] . As reported
earlier, WTpS3 transactivated this promoter approximately SO-fold compared to the
vector while most of our tumor-derived mutant pS3 proteins were unable to elicit any
response (Figure 1 4) [ 1 96].

Mutant pS3-D28 1 G and pS3-R282W transactivated this

promoter a minimum of five to six fold, though this is 1 0-fold less than the
transactivation observed with WTpS3 .
Mutants o f p S 3 used i n this study were also analyzed for their ability to repress
promoters normally inhibited by WTpS3 [34, 3S, 76, 1 34, I S3, 1 97] . For this purpose the
SV 40 early promoter contained within the pGL2 vector (Promega) was used as a
representative example.

Again, as reported earlier [ 1 97], WTpS3 transcriptionally

inhibited this promoter approximately 1 0-fold.

The inhibitory effects of mutant pS3

varied appreciably, pS3- R I 7 S H lost 1 00% of its inhibitory effects; while pS3-R273 H and
pS3-H 1 79Y

lost

approximately

SO%

(Figure

I S).

Interestingly,

pS3-D28 1 G
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transactivated this promoter.

The reasons why this occurs are stil l unknown.

For

subsequent studies mutant p53-R 1 75H, -R273H and -02 8 1 G were selected for use as
The first two mutants were chosen as representative examples of structural

models.

(RI 75H) and contact (R273H) p53 mutants. The third, 028 1 G, was selected in order to
correlate results with experimental data already avai lable in the l iterature.
Figure 15. Transcriptional activation of p53 -repressed promoters by mutant p53 .

�
t.-

0
.;;:
.=
"
«

..

2

�
'u

300
250
200
1 50

:I
...l

1 00

.�

50

cc::

0

..

.!!..

SV40 Early Promoter.Luc

350

E
'"
a:l
:>
E
u
0.

'"
V')
0.

�

-<

'"
....

�
V')
0.

u..

rV')

'"
V')
0.

u
'"
>00

�
V')
0.

:r:
V')
r-

'"
V')
0.

>0r-

'"
V')
0.

�
....
:'::
�
V')
0.

:r:
'"
rN
'"
V')
0.

0
oo
'":'
'"
V')
0.

�
N
00
N
'"
V')
0.

H 1 299 cells expressing p53-R I 75H, -R273H and -D28 1 G exhibit an increased
growth rate. H 1 299 (lung carcinoma) cells were used to generate stable transfectants

expressing one of three p53 mutants (-RI 75H, -R273H and -02 8 1 G). Additionally cells
l ines expressing a transactivation deficient form, p53-R175H (L22Q/W23S) or p53D28 1 G (L22Q/W23S), were also generated. This mutant of p53 contains two additional
mutations located within the transactivation domain of the protein [ 1 33]. Expression of
p53 was determined by western blot analysis (Figure 1 6).

C lones expressing similar

levels of p53 were selected for further experiments; asterisks in Figure 1 6 indicate clones
used in microarray hybridization analyses.

21 PT (breast carcinoma) and Saos-2

(osteosarcoma) cells expressing mutant p53 were also generated (data not shown).
Earlier data indicated that expression of mutant p53 in cells normally devoid of p53
may give a growth advantage [ 1 1 , 1 1 9, 1 34]. This notion was tested using a growth rate
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assay. Cells were plated at equal densities ( I x l Os cells per plate); one plate of each cell
line was seeded for each day of the assay. The data in Figure 1 7 show that mutant p53expressing H 1 299 cells proliferate at a higher rate compared to the vector control cell line
(HC-5).

This increased growth rate was also observed with different clones of H 1 299

expressing the same p53 mutant and H 1 299 cells expressing different mutant p53 forms
(R 1 75H or R273H). At least two clones of each cell line were tested with similar results,
decreasing the possibility that this characteristic is not due to a clonal variation (data not
shown).
Figure 1 6. Expression of mutant p53 in H 1 299 cells.
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Expression of the transactivation deficient mutant p53-02 8 1 G (L22Q/W23S) did not
increase the growth rate of cells as well as those expressing p53-028 1 G. This mutant
p53 is defective in gain-of-function as measured by the lack of increased tumorigenicity
when constitutively expressed in 1 0(3) cells, which become tumorigenic if p53-02 8 1 G is
stably expressed in these cells [ 1 33]. It has also been shown that this particular p53
mutant is defective in transactivation of the MORI and

c-myc

promoters, which are up

regulated by p53-028 1 G [ 1 33 , 1 34]. Since p53-D28 1 G (L22QIW23S) is defective in
transactivation, the lack of increased growth rate in cells expressing this mutant implies
that transactivation is necessary for this gain-of-function property of mutant p53 .
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RNAi against p53 decreases mutant p53 enhanced growth. To detennine whether

expression of mutant p53 remains directly related to the increased growth rate in H l 299
cells, we used p53-specific siRNA. H l 299 cells expressing p53-R 1 75H were transfected
with a double-stranded ribonucleotide sequence specific for p53 (or a non-specific
sequence as a control) 24 and 4Shrs prior to plating [ 1 9S ] . Cell viability and level of p53
were measured every day for up to five days after plating. Data presented in Figure I S
show that as the mutant p53 protein level decreases after siRNA transfection ( l SA, days
2-5), the number of viable cells remains similar to that of the control cells ( I SB, bottom
panel, days 3 -5).

This continues up to day 5 , after which the transient effect of the

siRNA diminishes. As the mutant p53 protein level begins to increase ( l SA, days 6-7), ·
cell viability also rises ( l SB, bottom panel, days 6-7), indicating that continuous mutant
p53 expression is necessary for the observed phenotype.
Figure 1 7. Mutant p53 expression results in enhanced growth rates in H 1 299 cells .
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Thus, there is a direct relationship between mutant p53 level and growth enhancement
in H 1 299 cells.

Control siRNA itself does not affect mutant p53 mediated growth

enhancement compared to vector control cells ( I 8B, upper panel).
experiment, levels of

c-myc,

In a parallel

a target of mutant p53, were examined after transfection

with siRNA directed against p53 (Figure 1 8C). Western blot analysis shows that both
p53 and

c-myc

levels decrease after transfection. Since the growth rate of mutant p53

expressing cells decreases after siRNA treatment, this suggests a possible involvement of
c-myc

in mutant p53 mediated increased growth rate phenotype in H 1 299 cells.

Figure 18. The increased growth rate phenotype is dependent on mutant p53
expressIon.
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8 1 299 cells expressing mutant p53 show decreased sensitivity to etoposide.

Earlier work by others has also shown that expression of mutant p53 in cells results in a
decreased sensitivity to chemotherapeutic drugs [ 1 28].

HI 299 cells stably expressing
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p53-R I 75H, -R273H, -D28 1 G (or transfected with vector alone) were tested for
decreased sensitivity to etoposide using colony formation assay. Data shown in Figure
1 9 indicate that cells expressing p53 mutants -RI 75H, -R273H and -D28 1 G are less
sensitive to etoposide than the cells stably transfected with vector alone. This is in accord
with results published by others using H 1 299 and other cell lines [ 1 28]. Expression of
the transactivation deficient mutant p53-D28 1 G (L22QIW23S) in H 1 299 cells did not
affect chemosensitivity of the cells to etoposide.
These results were recapitulated with H 1 299 pools and with 2 1 PT cell lines
expressing the same three p53 mutants (Figure 20 and data not shown). Furthermore, a
bromodeoxyuridine (BrdU) incorporation assay using the H 1 299 stable transfectants
shows increased DNA replication in cells expressing mutant p53 (but not the
L22Q/W23 S transactivation deficient protein) after drug exposure (data not shown).
Figure 1 9. Expression of mutant p53 in H 1 299 results in decreased sensitivity to
etoposide.
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As shown, cell lines expressing the transactivation deficient mutant p53 have a
disadvantage in etoposide-induced cell death suggesting a correlation between mutant
p53-mediated transactivation and the decreased chemosensitivity observed in cancer cells
expressing p53 mutants.

The mechanism behind this observation is unknown.

This

decreased ability of the cells to survive is perhaps due to the inability of the
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transactivation deficient mutant to up-regulate genes whose expression provides cells
protection against etoposide induce cell death.
Figure 20. Pools of mutant p53-expressing H l 299 cells recapitulate results obtained
earlier.
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Mutant p53 enhances the plating efficiency of Saos-2 cells in soft agar.

The

ability of Saos-2 cells to form colonies in soft agar was assayed as described earlier by
Dittmer e/ al. [ 1 1 ] . Once again, a transactivation deficient mutant p53 expressing cell
line was included in the assay. Saos-2 cells stably expressing mutant p53-D28 I G, p53D28 1 G (L22Q/W23S) or vector alone, were plated at a density of 3000 cells/well in 6well plates over a 0.5% agar plug: Cells were grown in 0.25% agar medium for 4-5
weeks with periodic additions of media. Approximately I % of vector-transfected cells
initially plated formed colonies, whereas mutant p53-D28 I G displayed an increased
ability to grow in soft agar (5- 1 0% above vector control cells). Cells expressing mutant
p53-D2 8 1 G (L22QIW23S) had a comparative growth of 2-3% (Figure 2 1 ). Additionally,
colonies of cells expressing mutant p53-D28 1 G were larger (approximately 3-4 fold) than
those formed by either vector or p53-D28 I G (L22Q/W23S) expressing cells (data not
shown).

Although, mutant p53 enhances the plating efficiency of Saos-2 cells,

expression of the transactivation deficient mutant did not completely reduce plating
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efficiency. This suggests that for this gain-of-function phenotype, transactivation may
not be the only factor involved.
Figure 2 1 . Mutant p53-expressing Saos-2 cells exhibit increased plating in soft agar.
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Chapter Summary.

Expression of mutant p53 resulted in increased growth rate (H 1 299 cells), decreased
chemosensitivity ( H 1 299 and 2 l PT cells) and increased plating efficiency (Saos-2 cells).
Expression of a transactivation deficient mutant p53 did not induce gain-of-function
properties (increased growth rate and decreased chemosensitivity). This supports the idea
that genes transactivated by mutant p53 may be responsible for these two gain-of
function phenotypes.
Unlike the other gain-of-function properties tested, soft agar plating efficiency in
Saos-2 cells was not significantly affected by the expression of the transactivation
deficient mutant, suggesting that transactivation may not be the only factor affecting this
gain-of-function property.

Perhaps this property is the result of both altered protein

protein interactions and transactivation.
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Chapter 5.
Modulation of Gene Expression by Tumor-Derived Mutant p53.

The work presented in this chapter has been published in the journals Oncogene and Cancer Research
(Oncogene. 2002 Jan 1 0;2 1 (2): 1 7 6-89. and Cancer Res. 2004 Oct 1 5;64(20):7447-54).

a. Introduction.

Since the data described above and earlier suggested that mutant p53-mediated
transactivation is necessary for its growth promoting functions, gene expression profiles
analyses were conducted using the H I 299 cell clones expressing mutant p53-R I 75H, R273H, or -D28 1 G in order to identify a possible pathway used by the mutant p53
proteins in inducing oncogenesis [ 1 1 9, 1 33 , 1 34].

b. Experimental results.
Mutant p53-RI75H, -R273H and -D28 1 G expression in H 1 299 cells affects a
common set of genes, including a number of growth-related genes.

The gene

expression profile of vector transfected H I 299 cells was used as controls. Affymetrix
U95Av2 arrays (HG-U95Av2) were used for the analyses. Hybridization signals were
normalized and filtered and changes in gene expression were detected in terms of S-score
for a given gene between two compared microarrays [ 1 99, 200) . The magnitude of the S
score represents the significance of change, thus an absolute value S-score greater than 2
represents a p-value

<

0.045, uncorrected for multiple comparisons. Scatter plot analyses

(Figure 22) of the S-scores show a very high degree of consistency of changes in gene
expression between biological duplicates.

The scatter-grams also indicate a relatively

large number of changes in gene expression in each of the mutant p53-expressing cell
lines versus the control cell lines.
In order to identify genes reproducibly affected by the expression of any mutant p53
in these cell lines, the S-score data was analyzed by a permutation method computer
program, Significance Analysis of Microarray (SAM) [20 1 ] . A SAM analysis of the S
scores has the advantage that small and subtle consistent changes reproduced across the
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array samples can be detected. A one-class analysis and a stringent False Discovery Rate
(FOR) of 0.3% were used so as to focus on the most reproducible changes evoked by the
p53 mutant across all hybridizations. One-hundred and eight (88 up-regulated, 20 down
regulated) genes were identified as having an altered expression in the mutant p53expressing cell lines. We found no WTp53 regulated genes such as p2 1 , MDM2, PUMA,
DDB2, ERCC5, GADD45 or Bax [37, 38] included in the list. On the other hand,

c-myc

and PCNA, which have been reported as up-regulated by mutant p53, were present in our
list of up-regulated genes. MDR l , BFGF, IL-6 and Bcl-2 were up-regulated minimally
and therefore are not included in our final list of genes [ 1 1 9, 1 53, 1 56, 1 90, 202, 203) .
Figure 22. Scatter-gram analysis o f S-scores generated.
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This type of analysis excludes those genes differentially affected by the p53 mutant
proteins, therefore, a cluster analysis of this list only reveals two major clusters
containing genes that are up-regulated or down-regulated in common by al1 three p53
mutants (Figure 23). In paral1eJ, microarray data obtained from H 1 299 cel1s infected
with adenovirus expressing WTp53 (or p-galactosidase control) were analyzed in a
similar manner (data not shown) and compared to the transcriptional profiles from the
mutant p53 expressing cel1 lines in order to determine the transcriptional response of the
genes in the presence of WTp53. Table 3 shows a representative example of the genes
identified as up-regulated in H 1 299 grouped in functional categories such as metastasis
(i.e. human myeloid cell differentiation protein or MCL 1 ), cel1 cycle (i.e. ASNS and
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E2F-5) [204, 205 ] , amino acid homeostasis (i.e. ASNS) [204] , transcriptional regulation
(i.e. Nuclear Factor-IL6) [206, 207], and cell survival (i.e. NF-KB2) [208, 209] . Among
the identified targets were the ASNS [204, 2 1 0-2 1 2] and the transcription factor NF
KB2 [208, 209].

Asparagine is a non-essential amino acid that has been reported as

regulating expression of genes involved in cell growth [2 1 1 , 2 1 2] .

Depletion of

asparagine can result in apoptosis and treatment of cancer with Asparaginase (ASNase),
an enzyme used in combination chemotherapy, can reportedly induce an apoptotic
response presumably through depletion of asparagine and asparagine synthetase
expression alone has been found to be sufficient to induce ASNase resistance in cells
[2 1 3, 2 1 4] . The transcription factor NF-KB2, on the other hand, has been implicated in
cell survival and chemoresistance, presenting a role for NF-KB2 [208, 209] .
Figure 23. Expression of mutant p53 in H 1 299 changes the cellular transcriptional
profile.
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Table 3 . Representative example o f genes up-regulated by mutant.

Gene Name

Function

glycyl-, threonyl-,
Amino acid and
Protein Synthesis

asparaginyl -tRNA synthetases
Asparagine synthetase*
(ASNS)

Cyelin H
CyC\in 82

Cell Cyele

cdc25A

S-score

Effect by

value

WTp53

U095 1 0;
M63 1 80;
084273

5.248;
3.69 1 ;
2.880

Repressed

M27396

5 .07 1

Repressed

Gene ban k No.

UI 1 79 1

2.035

Repressed

AL080 1 46

3 .327

Repressed

M 8 1 933

2.478

Repressed

AF052 135

2 . 1 99

Repressed

U 2 1 090

2.783

Repressed

X6 1 498

2.664

Repressed

3 .260

Repressed

3.171

Repressed

Associated molecule with the
SH3 domain of ST AM
(AMSH)

DNA Replication

DNA polymerase delta-2
(POLD2)

N F-kB, p52

Transcription

Transcription factor E2F-5
RNA polymerase II,
polypeptide E (RNA pollI E)

D82348
D38251

• Transcriptional up-rerulation of genes in bold lettering has been confIrmed by either QPCR or in vivo
transcriptional assays. NA Not A ffected.
=

The authenticity of changes in gene expression observed in the microarray analyses
was verified by quantitative polymerase chain reaction (QPCR) for a representative
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group of gene targets (Figure 24). Gene specific primers were designed to detect and
determine relative mRNA levels in cells expressing mutant p53 compared to control
cells. QPCR was performed using the Light Cycler (Roche) with the DNA-binding dye
SYBR Green (Molecular Probes) that binds to the minor grooves of the DNA double
helix. Total RNA was isolated from stably transfected H 1 299 cell lines expressing the
mutant p53 protein (-D2 8 I G-5, -R273H- 1 4 and -R 1 75H-72). The isolated RNA was
DNAse treated and reverse transcribed using commercial kits from Invitrogen to
generate the cDNA used in the experiment as described earlier [ 1 56]. Primers were
designed using Oligo 5 (Molecular Biology Insights).
Figure 24. QPCR analysis of cells expressing mutant p5 3 .
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the triple mutant p53-D28 1 G (L22Q/W23 S) were also examined by QPCR.

This

transactivation deficient mutant did not retain the ability to up-regulate expression of
mutant p53 target genes identified by the microarray expression analysis. As shown in
Figure 25, in all the cases examined, the presence of the two additional mutations within
the transactivation domain resulted in a significant loss of up-regulation compared to the
transactivating counterpart. The combined data presented indicates that transactivation
by tumor-derived p53 mutants is directly related to the mutant p53 protein's ability to
induce gain-of-function properties in cells in which they are expressed.
Promoters and cloned upstream sequences of a number of genes up-regulated by

To determine

p53 mutants are transactivated in transient transcriptional assays.

whether the promoters of some of the genes whose expression was found to be up
regulated are transactivated by mutant p53 in transient transcriptional assays, seven
promoters or presumptive promoters of the up-regulated genes were assayed.

The

presumptive promoters for angiopoietin 1 (ANGPT l ), integrin a6 (ITAG6), cyclin B2,
polymerase delta subunit 2 (POLD2) and E2F-5 were cloned from genomic DNA as
described in Materials and Methods using information obtained in the NCBI database.
Figure 25. Transactivation deficient mutant p53 fails to up-regulated genes in vivo .
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Functions of the promoters of estrogen responsive A9 (EBAG9) [2 1 5] and asparagine
synthetase (ASNS) [2 1 2] , and the presumptive promoters for ANGPT l , ITGA6, Cyclin
B2, POLD2 and E2F-5 were studied using a luciferase reporter plasmid and p53 null
human osteosarcoma Saos-2 cells [ 1 56] in the presence and absence of WT or mutant p53
expression plasmids. The results obtained show that mutant p53 can transactivate the
promoters tested (Figure 26).
Figure 26. Promoter analysis of genes identified by microarray analysis.

ASNS

ANG PT t

1 600
1400

- - - - - -- --

1200

--------

1 000

___

�

�

"'::
�
-

.
.

(,/

<

800
600

400

200

0

'"

o G'l

J:
M

�0.

M N
"'
0. N

�0.

0.

N
Cl

�

�

�

-----

-

-

-

--

-

-- -- -- -

.

--------

+--�--L,__
M
E
�
'"
'"
""
0.

(,/
=

�

--

--------

�

.�
..!

-- - -- - - ---

- - - - - - - -

U

�

-

- - -- - - --

::E

f

-

- - - - - - - -

00
>

�

- -- -- -- -

��

:::,

�

�0.

E
'"
00
>

::E

U

0.

�
0.

�

o
G'l
_ M

""
S
.;,
'"

0.

��
M N
"' N

0.

:::,

�0.

ITGA6

E B AG-9
1 400
1200
1 000

800

- -- - - --

-

- - - - - - - -

600

-- - - - - --

400

--------

200
o

+-----.--'--r-�
�
'"
""
0.
00
M

>

::E
�

�

N
Cl

�0.

o G'l

o;;9 0-�
��

�

�0.

�

00
>

::E

U

0.

M

'"

0.

�

""
S

�0.

o
G'l
_ M

��
M N
"'
0. N

:::,

a:
.;,
'"
0.

Similar results were obtained with the Cyclin B2, POLD2 and E2F-5 promoters (data
not shown). Although there is some variation among the p53 mutants, they all have the
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capacity to transactivate the promoters, suggesting a uniformity of function.

WTp53

repressed all the promoters tested. The transcriptional data from these promoters further
verifies the earlier results of the microarray hybridization analysis.
Other p53 mutants were also tested for transactivation of the ASNS promoter (Figure
27). As can be seen in the figure, the different mutants up-regulated the ASNS promoter
to various degrees, further suggesting that p53 mutants may induce oncogenic properties
through a common molecular mechanism.
Figure 27. Mutant p53 mediated transactivation of the ASNS gene.
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Figure 28. Mutant p53-R273H increases protein level expression of ASNS.
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Transactivation of the ASNS promoter by mutant p53 was concentration dependent
for p53-R273H and -D28 1 G. Furthermore, adenoviral infection of H l 299 cells with an
adenovirus expressing mutant p53 -R273H at increasing multiplicities of infection (MOl)
resulted in increased asparagine synthetase protein levels (Figure 28).
Chromatin immunoprecipitation reveals the presence of mutant p53 on the
ASNS and hTERT promoters. We carried out Chromatin Immunoprecipitation (ChIP)

[2 1 6] assays to determine the presence of mutant p53 in the promoter region of the ASNS
genes using antibodies specific for p53 or an IgG control. Cell extracts prepared from the
mutant p53-R273H expressing H 1 299 cell line were used for immunoprecipitation as
described in Experimental Methods. The presence of an ASNS promoter fragment in the
immunoprecipitated DNA was detected using specific PCR primers. QPCR analysis of
the immunoprecipitate reveals that mutant p53 localizes on the ASNS promoter (Figure
29).

The figure shows results from two independent immunoprecipitations. Each PCR

reaction was performed in duplicate.
Figure 29. Mutant p53 localizes on the ASNS promoter.
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c.

Chapter Summary.

Gain-of-function phenotypes are most likely the result of transcriptional changes
induced by the expression of mutant pS3 in cells.

It had been shown earlier that

transactivation deficient forms of mutant pS3 did not increase the tumorigenic potential
of 1 0(3) when inj ected into nude mice [ 1 3 3 , I S6] . Moreover, inhibition of mutant pS3
through RNA interference also decreased gain-of-function phenotypes [ 1 48]. Therefore,
in order to identify the genes responsible for the observed phenotypes, global gene
expression analyses were carried out using pS3-null H I 299 cells stably transfected to
express mutant pS3 (-R 1 7SH, -R273H and -D28 1 G).
A thorough and stringent analysis revealed I SO genes up-regulated by the expression
of mutant pS3 . These genes were inhibited or unaffected in the presence of WTpS3 . Up
regulation of a number of these genes was confirmed by QPCR and transient
transcriptional promoter analyses; expression of the transactivation deficient mutant pS3D28 1 G (L22QIW23S) did not result in up-regulation of the tested genes, further
supporting the idea that transactivation of genes is directly related to gain-of-function
phenotypes.

Using the ASNS gene promoter as a model, it was shown that

transactivation by mutant pS3-R273H and -D28 1 G was concentration dependent and that
the increased transcription did indeed result in increased ASNS protein levels. Finally,
using chromatin immunoprecipitations, localization of the mutant pS3-R273H protein
was detected on the ASNS promoter.
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M. Discussion.

Since the C-terminal region of wild-type p53 harbors the oligomerization domain, and
oligomerization is necessary for the biological functions of wild-type p53 [6, 23, 1 80,
1 9 1 , 2 1 7] , it was hypothesized that the C-terminal sequences for mutant p53 would be
required for oligomerization, and the oligomerization may be critical for gain-of-function
[ 1 34]. This hypothesis was tested using several different approaches.
First, the tetramerization domain of p53-D28 1 G was replaced with either a coiled-coil
dimerization domain from the yeast GCN4 protein (p53-D2 8 1 G 343cc) or a modified
coiled-coil domain that can act as a tetramerization motif (p5 3-D2 8 1 G TZN4).

The

transcriptional data generated with these heterologous constructs showed that mutant p53
required the C-terminally located oligomerization and non-sequence-specific nucleic
acid-binding domain for its transactivation properties (Figure 5). This requirement was
sequence-specific and not met by merely allowing the protein to oligomerize (Figure 6).
Similar experiments were carried out using WTp53 (data not shown). However, in the
context of WTp53, replacement of the tetramerization domain of WTp53 by the
dimerization domain (WTp53 343cc) could effectively sustain transactivation and growth
suppression functions of WTp53 [ 1 76, 1 78-1 80, 2 1 8], data not shown] .
Interestingly, the replacement of WTp53 ' s tetramerization domain by a derivative of
the coiled-coil structure resulting in a tetramerization domain could not induce
transcription from the human p2 1 promoter as well as p53 343cc (data not shown). The
reason for this apparent discrepancy is unknown, but could be related to the DNA
concentrations used in the different transfections [23] .

Also, the wild-type p53

derivatives inhibited the CMV immediate-early promoter significantly; the extent of
inhibition is comparable to that mediated by wild-type p53 (data not shown). Thus, the
functions of wild-type p53 were preserved using the various oligomerization domain
derivatives as was shown earlier [ 1 76, 1 78-1 80, 2 1 8] .
As a second approach, a N-termina1 deletion mutant o f p53 was used. This deletion
mutant retained the oligomerization domain but dispenses off the transactivation domain
and a large portion of the sequence-specific DNA-binding domain, inactivating the
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transactivation and DNA-binding activities of wild-type p53 [23 ] .

Co-transfection

followed by irnmunoprecipitation analysis showed that p53 del. 1 -293 forms hetero
oligomeric complexes with p53-D28 1 G (Figure 9). This interaction also inhibited mutant
p53-D2 8 1 G-mediated transactivation of the EGFR and MDRI promoters, suggesting that
hetero-oligomerization inactivates transcriptional functions of mutant p53 (Figures 7 and
8).

Interestingly, this decreased transactivation was only partial in stably transfected

murine 1 0(3) cells and although 1 0(3) cells stably transfected with p53-D28 1 G express 5
to 6-fold more PCNA and NF-KB2 mRNA compared to the cells transfected with vector
alone, co-expression of p53 del. 1 -293 reduced this transactivation only partially (Figure
1 0). The data, therefore, support the idea that proper oligomeric forms of mutant p53 are
required for its transactivation function.
Since replacement of the oligomerization domain of p53-D2 8 1 G inhibited the
transactivation ability of the mutant protein while having little of no effect in the context
of WTp53 , the data strongly suggest that the C-terminal region of WTp53 mainly
functions in oligomerization whereas in the context of mutant p53 it seems to perform
additional functions.

Thus, there is a clear distinction in the requirement of the C

terminal domain for wild-type and mutant p53-mediated transcriptional functions.

A

number of possible explanations for this requirement can be offered: 1 ) WTp53 has a
nucleic acid binding activity associated with its C-terminal region [9, 1 79] . It is possible
that under appropriate conditions mutant p53 utilizes this activity to interact with
promoter elements and other factors to drive transcription from a promoter. 2) A number
of post-translational modifications, such as phosphorylation and acetylation have been
reported to occur in specific sites located near the C-terminus of WTp53 [34, 35, 2 1 9] ;
perhaps mutant p53 requires these modifications for its transactivation function.

3)

Finally, the C-terminal region could b e a site for protein-protein interactions [i.e., c-abl,
[220]] needed for mutant p53-mediated transactivation. The over-expression of p53 del.
1 -293 would compete for such modifications or functions with the intact protein resulting
in inhibition or decrease in transactivation. Analyses involving more specific mutations
near the C-terminus along with functional assays are required before a comprehensive
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idea and solid conclusions about the function of the C-tenninus in mutant p53-mediated
transactivation can be made.
Since co-expression of p53 del. 1 -293 with p53-D28 1 G inhibited transactivation, it
was expected that this interaction would also inhibit gain-of-function properties. Results
shown in Tables I and 2, however, indicate that this is not the case. Co-expression of
p53 del. 1 -293 did not inhibit colony fonnation and tumorigenicity induced by mutant
p53-D2 8 I G.

Co-immunoprecipitation experiments showed that indeed these proteins

interact with each other in vivo (Figure I I ). Thus, hetero-oligomerization between p53D28 1 G and p53 del. 1 -293 may not inhibit the growth enhancing properties of the full
length p53-D28 1 G, although it does inhibit its transactivation property. This obserVation
seems to go against the notion that transactivation by tumor-derived p53 mutants may be
responsible for the gain-of-function.
It is necessary then to point out that before reaching such a conclusion, it must be first
shown that all the mutant p53 protein molecules are complexed with p53 del. 1 -293, and
that every complex in every stably transfected cell contains at least one molecule of p53
del. 1 -293 capable of inhibiting transactivation by the tetrameric complex. Although p53
del. 1 -293 and p53-D28 1 G can fonn hetero-oligomeric complexes in 1 0(3) cells, it is
possible that any free mutant p53 tetramer could induce the gain-of-function properties
observed. It is also possible that because of extended number of passages the cells have
gone through, the 1 0(3) cells expressing p53-D28 1 G became spontaneously transfonned
independent of the involvement of mutant p53-D28 1 G; in such a case inhibiting mutant
p53 transactivation activity would not decrease its oncogenic potential. Murine 1 0(3)
cells indeed have a tendency to spontaneously transfonn when cultured for prolonged
periods of time (Deb S., unpublished data). However, the conclusions that can be drawn
from this portion of the research are that mutant p53 requires both its C-tenninal
sequences and proper oligomerization for transactivation and gain-of-function properties.
Expression of gain-of-function p53 mutants has also been shown to increase the
growth rate of cells, decrease sensitivity to chemotherapeutic drugs, interfere with p53independent apoptosis, and induce centrosome abnonnalities in cells among other

51

properties [85, 1 24, 1 28, 1 42, 22 1 ].

Gualberto et at. [ 1 23] reported that some p53

mutants confer a dominant gain-of-function phenotype that disrupts the spindle
checkpoint control.

They have also shown that this property did not require the

transactivation function of mutant p53. Thus, it is possible that some gain-of-function
properties are achievable eyen in the absence of the transactivation function of mutant
p53 and may be solely due to protein-protein interactions.
This makes it necessary to identify which gain-of-function properties are dependent
on transactivation and which involve other mechanisms such as protein-protein
interactions. A study of various p53 mutants available in this laboratory using a colony
formation assay, revealed that the p53 mutants vary in their ability to induce a growth
advantage suggesting that these mutants have a tumorigenic potential (Figure 1 2).
Transcriptional reporter assays and EMSA analyses also showed that these mutants did
not bind the WTp53 DNA binding consensus site and were unable to properly
transactivate the human p2 1 and MDM2 promoters (Figures 1 3 and 1 4), showing that the
mutants lack WTp53 activity.
Using p53-RI 75H, -R273H and -D28 1 G as models, the data generated show that
expression of all three of these p53 mutants can induce increased growth rates in H 1 299
and 1 0(3) cells, decreased chemosensitivity in H 1 299 and 2 1 PT cells, and increased soft
agar plating efficiency in Saos-2 cells (Figures 1 7, 1 9-2 1 and data not shown). In all
three of the phenotypes studied, expression of a transactivation deficient mutant p53
decreased or nullified the observed phenotypes. Interestingly, in Saos-2 cells, expression
of this transactivation deficient form of mutant p53 did not completely nullify the ability
of the cells to plate in soft agar, suggesting that transactivation is not the only factor
involved in mediating this phenotype. This further supports previously reported data that
certain mutant p53 gain-of-function phenotypes can be achieved independent of
transactivation [ 1 70- 1 75].
Expression of mutant p53 remained directly related to the observed growth rate in
H 1 299 cells (Figure 1 8). Inhibition of mutant p53 expression through RNA interference
decreased the growth rate of cells to a rate comparable to that of control cells. Thus, the
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data generated not only suggest that expression of mutant p53 was responsible for the
phenotype, but that continuous expression of the mutant protein is necessary to maintain
the gain-of-function phenotype observed in these cells.

It was also observed that

decreasing the mutant p53 protein levels also decreased protein levels of

c-myc,

suggesting a possible role for this protein in mutant p53-mediated enhanced growth in
H 1 299 cells. Further experiments using this approach could be used to determine the
exact role of mutant p53 expression in other gain-of-function phenotypes.
In order to understand the mechanism behind the phenotypes observed In cells
expressing mutant p53, gene expression analyses were performed to study the
transcriptional changes that occur in cells when mutant p53 is expressed in them. Using
microarray hybridization analyses, a group of genes was identified as regulated by the
p53 mutants in the absence of WT.

QPC R data (Figure 24) suggests that our microarray

hybridization analysis is reliable. Some of the identified genes were found to be involved
in cell growth, survival, adhesion and angiogenesis (Table 3).

The finding that all three

p53 mutants transactivate a common set of genes (Figure 23) in the absence of WTp53 is
unique and provides highly significant information toward understanding mutant p53induced gain-of-function suggesting the existence of a common pathway utilized by p53
mutants to aid in oncogenesis.

Of the genes identified in our microarray, MCL ! ,

EBAG9, ANGPT l , ITGA6, NF-KB2 and E2F-5 have been reported as up-regulated in
various cancer types and established cell lines [205, 222-226]. Since information is not
available in the literature, it remains to be seen whether these genes are also up-regulated
in the natural context of the p53 mutation, i.e. in human cancers carrying a p53 mutation.
It is important to point out that some of the genes identified in these analyses function as
transcription factors (i.e. E2F-5 and NF-KB2), which suggests the possibility that some of
the genes modulated by p53 may be modulated through these transcription factors.
Further analyses will be necessary in order to sort out the array of genes modulated by
mutant p53 into primary and secondary targets. Nevertheless, it is very likely that the
genes modulated by mutant p53 identified here may play a role in the various gain-of
function phenotypes that have been attributed to mutant p53 in the literature.

For

S3

example, the transcription factor NF-KB2 has been implicated in cell survival and
chemoresistance, presenting a role for NF-kB2 [208, 209]. It is then possible that this
factor is somehow involved in chemoresistance brought about by the expression of
mutant p53 in cells (Appendix A).
Although the exact molecular mechanism behind the gain-of-function properties of
p53 mutants is yet to be completely clarified, transactivation of growth promoting genes
remains a strong candidate. Another possibility that has been proposed for the observed
gain-of-function properties is the neutralization of p73 and p63, two p53 family members
[227-229] . Both p73 and p63 share significant sequence similarity with p53, and are able
to transactivate promoters containing a WTp53 consensus site in their promoter region,
such as p2 1 /WAF I and MDM2. As with WTp53, over-expression of p73 or p63 can
result in apoptosis and cell cycle arrest [230] .

Although there is sequence similarity

between the oligomerization domains of the three proteins, WTp53 does not hetero
oligomerize with p73 and p63 [23 1 ] . More recent reports, on the other hand, suggest that
p53 mutants can interact with p73 and p63 and that these interactions occur via the DNA
binding domain (amino acids 1 00-293) of the mutant p53 protein [232-234].

This

functionally inactivates p73 (and p63) and there is evidence to suggest that this
interaction is responsible for the decreased sensitivity to chemotherapeutic drugs that is
observed in cells over-expressing mutant p53 [232, 233, 235]. However, data presented
in the literature also suggest that transactivation by mutant p53 is directly related to its
gain-of-function

properties.

The

transactivation

deficient

mutant

p53-D28 1 G

(L22QIW23S) contains the same amino acid mutation within the DNA-binding domain
as its transactivating counterpart (p53-D2 8 1 G).

This mutant then should be able to

interact with p73 and p63 and its expression in cells should result in decreased sensitivity
to chemotherapeutic drugs.

This is not the case in the H 1 299 cell culture model

presented above. Therefore, it is possible that this phenotype may require a combination
of transcriptional activation of certain genes as well as protein-protein interaction with
p73 , p63 and perhaps other proteins. Preliminary studies performed in the laboratory
suggest that although p73 is present in H l 299 cells, its interaction with mutant p53 is
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minimal [ [236] and data not shown]. Additionally, this transactivation deficient mutant
failed to promote tumorigenicity suggesting further complexities to mutant p53 gain-of
function [ 1 33].
In general, single amino acid changes have an effect in both the transactivation and
transrepression activities of p53 (Figures 1 4 and 1 5). This is likely due to the presence of
mutations within the DNA-binding domain [234]. Thus, a decreased ability to bind DNA
would result in a decrease in the transactivation and repression activities of p53 . This
does not explain however, the ability of certain p53 mutants to transactivate promoters of
genes (i.e. peNA, I L-6, BFGF, IGF-I, and others) [reviewed in [ 1 1 9, 1 53 , 1 90, 202]]. It
is known that mutant · p53-mediated transactivation does not require WTp53 DNA
binding sites, showing that the mechanism of transactivation by mutant p53 is distinct
from that of the WTp53 protein [ 1 1 9, 1 34, 1 55].
Three possible molecular explanations exist for mutant p53-mediated transactivation:
1 ) It may be that p53 mutants differ in their ability to recognize and bind responsive
elements, although there is no strong evidence so far for any mutant p53 consensus
sequence in the literature. In this case, mutant p53 proteins may possess a DNA binding
ability altogether distinct from the WT protein. Analyses of mutant p53 DNA binding
has revealed that the mutant p53 protein can physically associate with certain responsive
promoters indicating that mutant p53 proteins are targeted to DNA in a specific manner
[ 1 52, 237]. Intriguingly, sequence analysis of mutant p53 responsive promoters has yet
to show any sequence homology nor describe a mutant p53 specific response element.
The question still remains, if mutant p53 can associate with DNA, then how is this
occurring? It appears that the interaction of mutant p53 with DNA is determined by the
structure of DNA and not by sequence specific motifs [238, 239] . This possibility arises
from observations that mutant p53, but not WTp53 , binds with high affinity to Matrix
Attachment Regions (MAR) elements. MAR elements are polymorphic, have no known
consensus sequence and are distributed throughout the genome.

In vitro binding of

mutant p53 to MAR elements is largely dependent on the length of the DNA and not the
sequence [240] . This is further supported by findings that mutant p53 proteins bind with
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high affinity t o DNA sequences with a propensity to undergo structural transitions [24 1 ,
242]. The finding that transactivation of some promoters by mutant p53 requires both the
DNA binding and C-terminal domains seems to support this idea [ 1 34, 1 54, 1 56, 243] .
DNA structure-dependent recognition would explain the lack o f sequence similarity
between the various mutant p53 responsive promoters.

Searching for structural

similarities in the DNA rather than sequence motifs may be a more meaningful approach
to understanding mutant p53-mediated transactivation.
2) A second possibility is that mutant p53-mediated induction of mRNA, as judged by
microarray or QPCR analysis, is the result of stabilization of RNA by a post
transcriptional mechanism, although no direct evidence exists for this mechanism either.
The results of the promoter analyses suggest that RNA stabilization is not a mechanism
of mutant p53 mediated gene up-regulation, at least for the target genes identified here.
3) A third explanation for mutant p53-mediated transactivation is the possibility that
mutant p53 targets promoters regulated by other transcription factors. Mutant p53 has
been shown to interact with other sequence specific transcription and nuclear factors such
as

Sp l , ATF/CREB or NF-KB [244-246].

Sp l can interact with both WTp53 and

mutant p53 [247, 248]. While the interaction between WTp53 and Spl may be dynamic,
mutant p53 may become tethered to Sp 1 resulting in the up-regulation of genes. As such,
differences in levels of transcription can be accounted for by the identity of the
transcription factors involved, or by the relative affinity of the mutant p53 for the
transcription factor. This model of transactivation is presented in Figure 30.
Since different promoters behave differently towards p53 (WT or mutant), it is
possible that the arrangement of other transcription factors present on a promoter
influence the effects of p53 on the overall transcription of that promoter. While WTp53
inhibits Spl -mediated transcription by interfering with DNA binding of Sp l , mutant p53
seems to enhance the activation potential of Sp 1 [249] suggesting that stereo-specific
complexes containing either WT or mutant p53 are functionally different. On the other
hand, the regulation of WT and mutant p53 of MDRI involves different promoter regions
[250]. Taken together, proximity, arrangement and/or physical contact of the mutant p53
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with transcriptional factor(s) or complex(es) may determine the outcome of the
interaction.

Figure 30. Proposed model of transactivation.
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In fact, a computer-based sequence analysis of genes listed in Table 3 reveals that
several of the genes identified here contain Sp 1 sites reportedly involved in the
transcriptional regulation of the gene (Figure 30). Mutant p53 transactivation may indeed
function through these sites. Using an algorithm designed by Hoh et al. [25 1 ] to find
presumptive p53-binding sites on the upstream sequences (approximately 2000bp up
stream from the 5'end of the mRNA) of genes listed in Table 1 it was observed that only
in a few cases there were reasonable sites that may bind WTp53 (data not shown). These
sites may play a role in WTp53-transcriptional repression of these promoters, a prediction
that remains to be tested in the future.

In other cases WTp53 must be repressing by

utilizing protein-protein interactions [252, 253]. Whether mutant p53 utilizes any of the
WTp53 binding sites or not is an open question, although perhaps unlikely.
The observations reported here may help formulate the role of mutant p53 in
oncogenesis and attempts to explain why tumors expressing mutant p53 have a poorer
prognosis. In a normal cell both the alleles of p53 are WT and p53 has full potency as a
"protector" against stress situations such as DNA damage principally acting as a
transcriptional activator. Because of a mutation in one of the alleles affecting the coding
sequence of p53, a faulty mutant protein with one amino acid substitution is produced.
Mutant p53 becomes stabilized weakening the transcriptional function of the WT protein.
This may eventually lead to the loss of the remaining WTp53 aBele, a question that has
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yet to be answered in the literature. This loss of heterozygosity has been reported in
many human cancers expressing mutant p53 [6, 20-22, 79-84]. The mutant protein then
begins working as a potential oncogenic agent transcriptionally activating growth
promoting, angiogenic and invasive genes leading to aggressive oncogenic phenotypes
observed in these cells.
Figure 31. Presumptive promoters of ASNS, E2F-5, EBAG9 and CDC25A.
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If one considers transcriptional regulation by WTp53 to be complex, then
transcriptional regulation by mutant p53 appears to be even more complex.

This

complexity seems to arise from the fact that several rather distinct mechanisms appear to
play a role in mutant p53 -mediated regulation of transcription, resulting in the altered
gene expression.

This would explain the cell type specific gene expression changes

associated with mutant p53 expression and the apparent difficulties in deciphering the
mechanisms underlying mutant p53 oncogenicity and gain-of-function properties
(Appendix B).

This makes it important to identify transcriptional targets common to

multiple p53 mutants.

Definition of this pathway and the molecular mechanisms

dictating it will provide strong candidates for cancer therapy development.
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N. Figure and Table Legends.

Figure 1.

Structure of p53.

Graphical representation of the various identified

domains with the p53 protein.
Figure 2. Functions of p53. Cellular damage results in the stabilization of p53 as a

result of phosphorylation and acetylation. The p53 protein can then act as a transcription
factor inducing up-regulation and down-regulation of various genes or as a structural
component of protein complexes. Cells are halted at various checkpoints during the cell
cycle or targeted for apoptosis.
Figure 3. Differences between mutant and WTp53. Transcriptional activation by

WTp53 leads to modulation of genes involved in tumor suppression.

This is largely

dependent on the ability of WTp53 to bind to its consensus sequence.

Mutant p53

expression, on the other hand, can lead to modulation of genes involved in tumor
progression even in the absence of WTp53 (gain-of-function) [254].
Figure 4. Schematic representation of p53-D28 1 G oligomerization derivatives.

Schematic representation of p53-D28 1 G derivatives used in the domain exchange
experiments. The tetramerization domain of p53 amino acid 320-360 is shown by a black
box. p53-D28 1 G TZ334NR has sequences from amino acids 334 to 393 replaced by a
modified coiled-coil structural domain (green box), p53-D28 1 G TZ334NRl352 has the
sequences 352-393 inserted after amino acid 352 following the TZ moiety, p53-D2 8 1 G
343cc has sequences from amino acids 344 to 393 replaced by the coiled-coil structural
domain (red box) coding for a dimerization motif from the yeast GCN4 protein.
Figure 5. Replacement of the tetramerization domain of mutant p53 has a
drastic effect on mutant p53-mediated transactivation.

Saos-2 cells were co

transfected with EGFR.Luc (200ng) and the expression plasmid for tumor-derived mutant
p53-D28I G, one of its derivatives or empty vector (800ng) in a 24-well plate using
Lipofectarnine 2000. Cell lysates were prepared 48hrs after transfection, and luciferase
activity measured. Western blot analysis from a representative transfection showed equal
protein expression (right inset).
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Figure 6. Replacement of the tetramerization domain of mutant p53 preserves
tetramerization of the protein. In vitro translated p53-D2 8 1 G and its derivatives (p53D28 1 G TZ334NR, p53-D28 1 G TZ3 34NR1352 and p53-D28 1 G del. 393-327) were
incubated with the indicated concentrations of glutaraldehyde [23]. Samples were
separated on a gradient (4-20%) SDS-PAGE after cross-linking. The gel was dried and
autoradiographed. Positions of presumptive monomers, dimers, trimers and tetramers of
p53 derivatives are indicated.
Figure 7. Transactivation of the EGFR promoter by tumor-derived mutant p53D281 G is inhibited by co-expression of p53 del. 1 -293. Saos-2 cells were plated at
. equal densities in 24-well plates and transfected 24hrs later. Each well was transfected
with l 70ng of EGFR.Luc, 1 70ng of pCMVBam p53-D2 8 1 G (or vector alone) and 5 l Ong
of pCMVBam p53 del. 1 -293 (or vector alone). Forty-eight hours after transfection, cell
extracts were prepared and luciferase activity measured.

Western blot analysis was

carried out with equal amounts of protein from a representative transfection to evaluate
protein expression (right inset).
Figure 8. Transactivation of the MDR1 promoter by tumor-derived mutant p53D281 G is inhibited by co-expression of p53 del. 1-293. Saos-2 cells were plated at
equal densities in 1 0cm plates and transfected the following day using the calcium
phosphate precipitation method.

Cells were transfected with 2.5J.lg of MDR l .CAT,

2.5J.lg of pCMVBam p53-D28 1 G (or vector alone) and 7.5J.lg of pCMVBam p53 del. 1 293 (or vector alone). After transfection, cells were treated as described in Experimental
Methods and CAT assays performed. Western blot analysis was carried out with equal
amounts of protein from a representative transfection to evaluate protein expression (right
inset).
Figure 9. p53 del. 1 -293 co-immunoprecipitates with p53-D281G. Saos-2 cells
were transfected in 1 0cm plates with 3 .2J.lg of the expression plasmid for p53-D28 1 G (or
expression vector alone) and 9.6J.lg of an expression plasmid for p53 del. 1 -293 (or
expression vector alone).

Twenty-four hours after transfection, cellular proteins were

labeled in vivo by 35 S-methionine. Extracts were then prepared and immunoprecipitated
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with monoclonal antibodies as depicted in the figure.

The immunoprecipitates were

resolved in a 1 5% SDS-polyacrylamide gel followed by autoradiography. The left panel
shows the binding sites for monoclonal antibodies PAb421 and DO l on p53-D28 1 G.
Figure 1 0.

Co-expression of p53 del. 1-293 inhibits transactivation by p53-

D281 G. Total RNA was prepared from 1 0(3) cells stably transfected with vector alone,
p53-D28 1 G, p53 del. 1 -293, or p53-D28 1 G and p53 del. 1 -293. Quantitative real time
PCR was perfonned to detennine the relative amounts of mRNA for NF-KB2 and PCNA
genes. Graphs show the relative levels of PCNA and NF-KB2 mRNAs (nonnalized to
GAPDH levels within the cells) in different stable transfectants of 1 0(3) cells.
Table 1. Colony formation in 10(3) cells stably transfected with vector or p53D281 G.

1 0(3) cells stably transfected with the vector pCMVBam Neo [255] or stably

expressing p53-D28 1 G [ 1 34] were transfected with I J.lg of pHyg and 5J.lg of the indicated
p53 or p73 expression plasmid [23, 1 88, 1 97] . Transfections were carried out by the
calcium phosphate precipitation method [ 1 34] . After 48hrs, cells were sub-cultured 1 :4
and allowed to fonn colonies in the presence of hygromycin (200 J.lg/ml). The media was
changed every 2-3 days. After 3 weeks, cells were fixed with methanol and stained by
methelyne blue.
Table 2.

Tumorigenicity of 10(3) cells expressing p53 derivatives.

The

tumorigenic potential of 1 0(3) cells expressing p53 derivatives was tested using nude
mice. Cells (5 x 1 06 per site) were subcutaneously injected into flanks of athymic nude
mice (National Cancer Institute) and tumor development was monitored as described
[ 1 1 ] ; [ 1 34].
Figure 1 1 . Hetero-oligomers are produced between p53-D281 G and p53 del. 1293 in 1 0(3) cells stably expressing the two proteins. Cell extracts from 1 0(3) cells
expressing p53 del. 1 -293 alone or expressing p53-D2 8 1 G and p53 del. 1 -293 were
prepared and immunoprecipitation reactions perfonned with the antibody DO l
(Oncogene, Ab-6).

The immunoprecipitates were then separated by SDS-PAGE

followed by western blot analysis. The blot was developed with PAb42 1 . Antibody DO l
was run as a control to depict the positions of light and heavy chains of IgG. Positions of
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molecular weight markers are shown.

The figure shows results from duplicate

irnmnoprecipitations.
Figure 12. Expression of tumor-derived mutant p53 increases the formation of
6
neomycin resistant colonies. 1 0(3) cells were plated at equal densities ( 1 0 cells per
plate) 24 hrs prior to transfection.

Cells were transfected with pCMV-Bam Neo and

WTp53 or mutant p53 (or vector alone) using the calcium phosphate precipitation
method. The cells were subcultured 1 :4 48 hrs after transfection and Neomycin (G4 1 8)
was added to start the selection process. After 3 weeks, cells were fixed with methanol
and stained; colonies containing more than thirty cells were counted. The final counts
were as follows: ( 1 ) pCMV-Bam: 4 1 , 3 1 , 42 Avg. 3 8 (2) pCMV-Bain WTp53 : 24, 25, 24
Avg. 24.3 , (3) pCMV-Bam p53-V I 43A: 55, 48, 65 Avg. 56, (4) pCMV-Bam p53-L l 57F:
39, 34, 45 Avg. 39.3, (5) pCMV-Bam p53- 1 63 C : 64, 63, 73 Avg. 66.7, (6) pCMV-Bam
p53-R I 75H: 88, 77, 95 Avg. 86.7, (7) pCMV-Bam p53- 1 79Y: 42, 44, 5 1 Avg. 43, (8)
pCMV-Bam p53- 1 94R 60, 58, 5 1 Avg. 56.3, (9) pCMV-Bam p53-R273 H : 1 1 2, 1 1 0, 1 06
Avg. 1 09.3, ( 1 0) pCMV-Bam p53-D28 1 G: 1 24, 1 29, 1 3 7 Avg. 1 30, and ( 1 1 ) pCMV
Bam p53-R282W: 72, 60, 68 Avg. 66.7.

The figure shows the number of average

colonies formed.
Figure 13.

DNA binding of WT and tumor-derived p53 mutants. Saos-2 cells

were transfected with 1 0J.lg of the expression plasmid containing WT or mutant p53,
whole cell extracts were prepared as described in Experimental Methods and DNA
binding reactions carried out as described in the text. The probe (P2 1 WT) used contained
the p53 binding sequence found in the p2 1 promoter (distal site).

Lanes 1 -5 were

incubated with purified p53 protein ( 1 00 ng), lanes 6-23 were incubated with an extract
obtained from whole cell Iysates containing approximately 1 0J.lg of total protein. WTp53
can bind the probe sequence containing the p53 -binding sites (Lanes 2 - 1 2).

A cold

competitor (P2 1 WT, lanes 2, 3, 8, 9) and a non-specific competitor (P2 1 MT, lanes 4, 5 ,
1 0, 1 1 ) were also used. A p53-specific antibody (Ab-6, Oncogene) was used t o generate
a supershift of the p53 -bound probe (lane 1 2).

Tumor-derived p53 mutants were
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analyzed for DNA binding to the same probe set (lanes 1 3-23). No binding was detected
for these tumor-derived p53 mutants
Figure 1 4.
p53.

Transcriptional activation of p53-inducible promoters by mutant

Human osteosarcoma Saos-2 cells were transfected using Lipofectamine 2000

(Invitrogen) with p2 1 .Luc or MDM2. Luc (200ng), and the expression vector containing
the WT or mutant p53 cDNA (25ng with p2 1 . 1uc, 1 00ng with MDM2.Luc). Cells were
grown for forty-eight hours, cell lysates prepared, and luciferase activity measured. The
vector reading was set to 1 00 and the relative luciferase activity in the remaining extracts
calculated with respect to the vector. Western blot analysis was performed to confirm
equal expression of the protein after transfection in a representative experiment using the
specific antibody P Ab 1 80 1 (data not shown).
Figure 15.
p53.

Transcriptional activation of p53-repressed promoters by mutant

Human osteosarcoma Saos-2 cells were transfected using Lipofectamine 2000

(Invitrogen) with SV40. Luc (200ng), and the expression vector containing the WT or
mutant p53 cDNA (800ng). Cells were grown for forty-eight hours, cell lysates prepared,
and luciferase activity was measured. The vector reading was set to 1 00 and the relative
luciferase activity in the remaining extracts calculated with respect to the vector.
Western blot analysis was performed to confirm equal expression of the protein after
transfection in a representative experiment using the specific antibody PAb 1 80 1 (data not
shown).
Figure 16. Expression of mutant p53 in 8 1299 cells. Human p53-null H 1 299 cells
were transfected using Lipofectamine 2000 (Invitrogen) with expression plasmids for
mutant p53 (or vector alone) as indicated. Forty-eight hours after transfection, cells were
sub-cultured 1 :3 and neomycin added at a concentration of 400 Ilg/ml to begin the
selection process.

After 3-4 weeks of selection, individual colonies were cultured

independently and checked for p53 expression using the antibody Pab 1 80 1 . Clones with
similar expression levels were selected for microarray hybridization analyses. Asterisks
indicate cell lines used for microarray hybridizations analyses.
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Figure 1 7.

Mutant p53 expression results in enhance growth rates in 9 1 299

cells. Cells were seeded at a density of I x 1 05 cells per 60mm plate. Five plates of each
cell line were plated initially (Day 0).

One plate of each was trypsinized, and cells

suspended in I ml of serum containing media. Cells were counted and the total number of
cells calculated and plotted for each day.
run

independent experiments

simultaneously.

Standard deviations result from three
Mutant-pS3 expressing cell lines were

compared to the control cell line HC-S . Only days 2-S are shown.
Figure 1 8. The increased growth rate phenotype is dependent on mutant p53
expression. H I 299 cells expressing pS3-R I 7S H or vector alone (HC-S) were transfected
using Lipofectamine 2000 with siRNA directed against pS3 ('pS3 ' ) or a non-specific
control sequence ('C').
24hrs later.

Cells were transfected a second time with the same siRNAs

A. Mutant pS3 protein levels were detected 2 to 7 days after the first

transfection using the antibody PAb 1 80 I in a parallel experiment; �-actin was used as a
loading control .

B. Transfected cells were plated at equal density 48hrs after the first

transfection (Day 2) in 96-well plates. Cell viability was measured using an MTS assay
kit (Promega) for the following five days. Viability of cell lines transfected with control
siRNA (top) or siRNA directed against pS3 (bottom). Cell viability is expressed as a
percentage of HC-S control cells on the indicated day.

C.

In a separate experiment,

H I 299 cells transfected with siRNA against pS3 were harvested 48hrs after transfection
and equal amounts of protein separated by SDS-PAGE. C-myc and pS3 were detected
using the specific antibodies (Oncogene, Ab-6 and Ab- I ).
Figure 1 9. Expression of mutant p53 in 9 1299 results in decreased sensitivity to
etoposide. Cells were plated at S x 1 04 cells/plate and treated with 61lM etoposide (final
concentration) for 48hrs.

After treatment, cells were washed with HBSS and the

surviving cells allowed to recuperate for three weeks with periodic changes of media.
The colonies formed were fixed with methanol, stained with methylene blue and counted.
The data shown is representative of three independent experiments

run

simultaneously;

colony numbers were adjusted to account for plating differences based on control plates.
Control plates were plated at one-tenth the density and treated with an equal amount of
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vehicle control (OMSO) for 48hrs with less than 1 0% plating difference (data not
shown).

Clones H l 299 cells expressing mutant p53-R I 75H, -R273H, -028 1 G, p53-

028 1 G (L22Q/W23 S) or vector alone were used.
Figure 20.

Pools of mutant p53-expressing 8 1 299 cells recapitulate results
4
obtained with individual clones. Cells were plated at 5 x 1 0 cells/plate and treated
with 61lM etoposide (final concentration) for 48hrs. After treatment, cells were washed
with HBSS and the surviving cells allowed to recuperate for three weeks with periodic
changes of media.

The colonies formed were fixed with methanol, stained with

methylene blue and counted.
experiments

run

The data shown is representative of three independent

simultaneously; colony numbers were adjusted to account for plating

differences based on control plates.

Control plates were plated at one-tenth the cell

density and treated with an equal amount of vehicle control (OMSO) for 48hrs with less
than 1 0% plating difference (data not shown).

Pools of H 1 299 cells expressing p53-

R 1 75H, p53-R 1 75 H (L22Q/W23S), -R273H, -028 1 G, or vector alone were used.
Figure 2 1 . Mutant p53-expressing Saos-2 cells exhibit increased plating in soft
agar.

Saos-2 cells expressing mutant p53-028 1 G, the transactivation deficient p53-

028 1 G (L22Q/W23S) or vector alone were plated at a density of 3000 cells/well in 6well plates over a .5% agar plug. Cells were grown in .25% agar medium for 4-5 weeks
with periodic additions of media. Approximately I % of vector-transfected cells formed
colonies, whereas mutant p53-02 8 1 G displayed an increased ability (5- 1 0%) to grow in
soft agar. Cells expressing mutant p53-028 1 G (L22Q/W23S) had a comparative growth
of 2-3%.
Figure 22. Scatter-gram analysis of S-scores generated. Scatter plot analyses of
the S-scores obtained after analysis of the microarray hybridization data.

The plot

represents two unpaired comparisons (mutant p53 expressing vs. vector control cells)
graphed against each other. The plots show a very high degree of consistency of changes
in gene expression between biological duplicates.

The scattergrams also indicate a

relatively large number of changes in gene expression in each of the mutant p53-
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expressing cell lines versus the control cell line. Clustering of the points around zero
would have indicated few or no changes occurring.
Figure 23.

Expression of mutant p53 in H 1 299 changes the cellular

transcriptional profile. Cluster analysis of the output gene list obtained from our SAM
analysis of the H 1 299.

Microarray hybridization analysis of cell clones expressing

mutant p53 (-R 1 75H, -R273 H and -D28 1 G) derived from H 1 299 cells using Affymetrix
GeneChipTM System U95Av2 chip reveals the up-regulation of a set of 1 50 genes up
regulated in the presence of all three p53 mutants, but identified as inhibited or
unaffected by WTp53 (not shown). Changes in gene expression were detected in terms of
statistical significance (S-score) of change in expression for a given gene between two
microarrays.

WTp53 hybridizations were generated from WTp53 infected cells

compared to �-galactosidase infected samples (data not shown).

The Cluster and

TreeView programs (http://rana.lbl.govl) were used to provide graphical displays of the
gene expression patterns [256, 257].
removed for ease of viewing. FDR

=

Gene names and accession numbers have been

0.3%

Table 3. Microarray hybridization analysis of RNA from H 1 299 cells expressing
mutant p53-RI 75H, -R273H and -D28 1 G in comparison to vector transfected cells.
Only up-regulated genes are listed on the table. Initial functional grouping of the genes
was performed with the EASE program [258].
Figure 24. QPCR analysis of cells expressing mutant p53. mRNA was extracted
from exponentially growing plates of the indicated cell lines and cDNA prepared. The
cDNA was then analyzed by QPCR using gene-specific primers for various genes
identified through microarray hybridization analysis.

The degree of expression was

quantitated using a relative standard curve and normalized to an internal control [Brome
Mosaic Virus (BMV) RNA] corresponding to the cDNA batch ( 1 56]. The normalized
mRNA level in the HC-5 control cell line was arbitrarily set to 1 and the relative fold
difference calculated for the remaining samples.
Figure 25.

Transactivation deficient mutant p53 fails to up-regulate genes in

vivo. mRNA was extracted from exponentially growing plates of the indicated cell lines
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and cDNA prepared.

The cDNA was then analyzed by QPCR using gene-specific

primers for various genes identified through microarray hybridization analysis as up
regulated by mutant p53 .

The degree of expression was quantitated using a relative

standard curve and normalized to an internal control [Brome Mosaic Virus (BMV) RNA]
corresponding to the cDNA batch [ 1 56].

The normalized mRNA level in the HC-5

control cell line was arbitrarily set to 1 and the relative fold difference calculated for the
remaining samples.
Figure 26.

Promoter analysis of a group of representative genes identified by

microarray analysis. The presumptive promoters for ANGPTl and ITGA6 were cloned
from genomic DNA using information obtained in the NCB! database (see Materials and
Methods).
[2 1 2 , 2 1 5] .

The promoters of ASNS and EBAG9 were obtained from outside sources
Promoters were studied using reporter luciferase constructs and p53 null

human osteosarcoma Saos-2 cells as described in Experimental Methods. The vector
reading was arbitrarily set to 1 00.
Figure 27.

Mutant p53 mediated transactivation of the ASNS gene.

Human

osteosarcoma Saos-2 cells were transfected with 200ng of ASNS.Luc and 250ng of the
expression vector for WT or mutant p53 as indicated. Cell lysates were prepared 48hrs
after transfection and luciferase activity was measured. The vector reading was set to
1 00 and the relative luciferase activity in the remaining extracts calculated with respect to
the vector.

Western blot analysis was performed to confirm equal expression of the

protein after transfection in a representative experiment using the specific antibody
PAb 1 80 1 (data not shown).
Figure 28. Mutant p53-R273H increases protein level expression of ASNS. Right
panel. Saos-2 cells were transfected with 200ng of ASNS.Luc and increasing amounts of
mutant p53 expression plasmid (p53-R273H or -D2 8 1 G) as indicated. Cell lysates were
prepared and luciferase activity was measured 48hrs after transfection.
reading was set to 1 00.

The vector

Left panel. H l 299 cells were plated at equal densities and

infected with increasing multiplicities of infection 24 hrs later using an adenovirus
expressing mutant p53-R273H (or �-gal as a control). Cell lysates were prepared 48hrs
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later and western blotting performed to detect protein levels of ASNS (upper panel).
Samples were normalized based on total protein readings. Actin was used as a loading
control (lower panel).

H 1 299 cells transiently transfected with an expression plasmid

containing the ASNS cDNA were used as a positive control.
Figure 29. Mutant p53 localizes on the ASNS promoter. Exponentially growing
cells of H-273H- 1 4 cell line were crosslinked, and harvested as described in
Experimental Methods.

p53 was immunoprecipitated using the specified antibody

(DO 1 ). Normal IgG was used in the control immunoprecipitation. The presence of the
ASNS promoters in the immunoprecipitate was detected using QPCR specific primers.
The graph shows the fold difference in Antibody/Input ratio of the QPCR signals
obtained for the specified antibody in two independent immunoprecipitation experiments.
The average fold difference for the signals and standard deviations were also calculated
(right).
Figure 30.

Proposed model of transactivation.

Left panel: Schematic

representation of WTp53 repressed NF-KB2 promoter. WTp53 localizes on the promoter
region by binding to other transcription factors (i.e. Sp l , NF-KB, etc).

Repression of

transcription occurs through the action of a co-repressor protein such as mSin3 or Histone
deacetylase (HDAC) [259]. Right panel: We propose that mutant p53 retains the ability
to bind some transcription factors. Therefore, it is possible for mutant p53 to localize on
the promoter by binding to Sp l or another transcription factor but is unable to repress
transcription since it has lost the ability to bind the co-repressor.

The intact

transactivation domain of the mutant protein can then interact with the RNA polymerase
complex, independently or through a co-activator thus increasing transcription of the
gene.
Figure 3 1 . Presumptive promoters of ASNS, E2F-5, EBAG9 and CDC25A.

The

transcription factor binding sites were identified using a world wide web base search
program

(TFSEARCH-

Transcription

http://www .cbrc.jp/researchidbITFSEARCH.html).

Binding

search)

found

at

Only those binding sites with high
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probability (>90%) are shown. The presumptive transcription initiation site is denoted by
a black upright bar and the ATG codon by a horizontal bar.
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o. Experimental Methods.

General Methods.
Plasmids and DNA. The p53 and p73 expression plasmids contained the human p53
and p73 cDNAs under the regulation of the CMV immediate-early promoter in the
pCMVBam expression vector [ 1 88, 255). The N-terminal deletion derivative p53 del. 1 293 was generated in the context of the human wild-type p53 cDNA as described earlier
[23) . p73a and p73 p cDNAs were cloned in such a way that they have a FLAG epitope
at the N-terminus when converted into the respective proteins [ 1 97).
The p53 C-terminal derivatives have been described earlier [ 1 78, 1 80).

The p53

343cc had sequences from amino acids 344-393 replaced with the coiled-coil structural
domain from the yeast GCN4 protein, while p53 TZ334NR had sequences from amino
acids 334-393 replaced by a modified coiled-coil structure defining a tetramerization
domain.

The p53-D2 8 1 G forms of these derivatives contained the amino acid

substitution at the position 2 8 1 from Arg to Gly; these clones were constructed by
standard sub-cloning techniques by replacing a restriction fragment of the wild-type p53
cDNA overlapping the sequence coding for amino acid 2 8 1 with the corresponding
fragment from p53-D28 1 G cDNA. All coding sequences were cloned in the pCMVBam
vector in the correct orientation downstream of the CMV immediate-early promoter.
The chloramphenicol acetyltransferase (CAT) plasmids utilized the Escherichia coli
CAT gene under the transcriptional control of the MDRI [ 1 34] promoter. The luciferase
plasmids used the firefly luciferase (Iuc) gene under the control of the human EGFR and
p2 1 promoters [40, 1 97). The p53 mutants (p53-V I 57F, p53-Y I 63C, p53-H I 79Y, p53L l 94R, p53-R282W) in pCMV-Bam used in this study were generated using the Quick
Change Site directed Mutagenesis (Stratagene) following the manufacturer's protocol.
Sequencing was performed after mutagenesis to confirm the presence of the desired
mutation. pCMV-Bam WTp53, p53-V I 43A, p53-RI 75H, p53-R273H, and p53-D2 8 1 G
were described earlier [ 1 56] . MDM2.Luc, p2 1 .Luc, and c-myc.Luc [40, 1 97] , ASNS.Luc
[2 1 1 , 2 1 2] and hTERT.Luc [260] have been described earlier.
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Generation of stable cell lines expressing mutant p53. The p53-null human lung
carcinoma cell lines H l 299 [26 1 ], human 2 1 PT [262], human Saos-2 [ 1 56]

and the

murine fibroblast 1 0(3) cell line were transfected using Lipofectamine 2000 or the
calcium phosphate method [ 1 88] with pCMVBam Neo or pCMVBam Neo-mutant p53
expression plasmid as indicated [255].

Control and mutant p53-expressing stable cell

lines were generated: 1 0(3) Vector 4 [ 1 0(3)-V4], 1 0(3) p53-D2 8 I G-clone 4 [ 1 0(3)
D28 I G-4], 2 l PT-control vector 5 [2 I PT-V5], 2 I PT-p53-RI 75H-clone 22 [2 I PT-RI 75H22], 2 I PT-p53-R273 H-clone 1 5 [2 I PT-R273H- 1 5] , 2 I PT-p53-D2 8 I G-clone 46 [2I PT
D28 I G-46], H l 299-control 5 [HC-5], H I 299-p53-D2 8 I G-clone 5 [H-D28 I G-5], H 1 299p53-R273 H-clone 14 [H-R273H- 1 4] , H I 299-p53-RI 75H-72 [H-R I 75H-72], p53-D2 8 1 G
(L22Q/W23S)-clones I I , 1 3 and 1 9 [H-D2 8 I G (L22Q/W23S)- I I , 1 3 and 1 9], Saos-2
control vector 2 and 4 [SC2 and SC4], Saos-2-p5 3-D28 I G clones 1 4 and 25 [S-D2 8 I G1 4 and 25] and Saos-2-p53-D2 8 I G (L22Q/W23S) clones

1 3 and 25 [S-D2 8 1 G

(L22QIW23S)- 1 4 and 25]. Additionally, stable pools of H l 299 expressing mutant p53R 1 75H, -R273H, -D2 8 1 G and -D2 8 1 G (L22Q/W23 S) were generated using the pIRES
Pur03 expression vector from Clontech.

Forty-eight hours after transfection the cells

were subcultured 1 :4 and grown in selective medium containing neomycin (G4 1 8) at a
concentration of 200 Ilg/ml [ 1 0(3)], 400 Ilg/ml [ H 1 299 and 2 I PT] or I mg/ml [Saos-2] to
start the selection process. The medium was changed periodically and after three weeks
of selection individual colonies were selected and analyzed for expression of p53 by
Western blotting as described [ 1 9 1 ] using the monoclonal antibody PAb l 80 1 . Several
clones from each transfection were expanded into cell lines.

The H I 299 pools were

generated using 2 Ilg/ml of puromycin.
Murine 1 0(3) cells [ I I ] or 1 0(3) cells stably expressing p53-D28 1 G [ 1 34] were
transfected with pCMVBam p53 del. 1 -293 and pCMVBam NEO [255] or pCMVBam
p53 del. 1 -293 and pHyg (Clontech), respectively, using the calcium phosphate
precipitation technique [ 1 88].

Forty-eight hours after transfection, cells were washed,

trypsinized, subcultured at I :4, and plated into selective medium supplemented with 200
Ilglml G-4 l 8 (active concentration) for previously untransfected 1 0(3) cells and 200
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flg/ml G-4 1 8 and 200 flg/ml hygromycin for p53-D28 1 G-expressing cells. Cells were
maintained in the selective medium with twice weekly changes of medium. Cells from
individual antibiotic-resistant colonies were isolated and expanded into cell lines.
Cell culture.

Human H 1 299 cells were maintained in RPMI 1 640 plus 1 0% Fetal

Bovine Serum (FBS).

2 1 PT cells were maintained in a-MEM plus 1 0% FBS and

indicated growth factors as described [262 ] .

Saos-2 cells were grown in DMEM plus

1 0% FBS and 5% Calf Serum (CS). 1 0(3) cells were grown in DMEM plus 1 0% FBS.
1 0(3) stable clones were grown in complete medium supplemented with the
corresponding selection agent.
Western blot analysis. Western blot analysis was carried out after SDS-PAGE using
monoclonal antibodies against p53 (Oncogene, Ab-6, pAb 1 80 1 or pAb42 1 as indicated)
or FLAG (Sigma) and a commercial kit (Promega) for labeling with an alkaline
phosphatase-conjugated secondary antibody following the manufacturer' s protocol.
Alternatively, proteins were detected using the ECL system (Amersham) following the
protocol prescribed by the vendor. Actin was detected with a mouse monoclonal �-actin
specific antibody (Sigma). C-myc was detected using a specific antibody (Oncogene, Ab1 ) and ASNS was detected using an antibody obtained from Dr. Michael Kilberg's
laboratory.

Chapter 3 Methods.
Luciferase assay.

Luciferase assays were carried olit using a commercial kit from

Promega as suggested by the vendor, and luminescence was measured in a Luminometer
made by Turner Designs. Cells were harvested 36-40hrs after transfection, and extracts
were prepared as suggested. As described for the CAT assay, equal amounts of protein
from each extract were used for the luciferase assay.

Relative luciferase activity was

plotted on the Y-axis and the value of the vector control was set to 1 00%.
Glutaraldehyde cross-linking. Analyses for the presence of oligomeric forms of
p53-D2 8 1 G and its derivatives were carried out as described [23 ] . Human p53-D28 1 G
and its derivatives were generated by a coupled in vitro transcription-translation system
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(Promega) and were incubated with glutaraldehyde at varying final concentrations at
3 7°C for 1 5 minutes. After cross-linking, proteins were boiled in 2X Laemmli loading
dye [23 ] , subjected to gradient (4-20%) SDS-PAGE, and visualized by autoradiography.
Chloramphenicol acetyltransferase assay.

Cells were harvested 36-40hrs post

transfection and lysed by three successive cycles of freezing and thawing. Extracts were
normalized for protein concentration and assayed for CAT enzyme activity as described
earlier [ 1 55 ] . Multiple independent experiments (three or more) were done to determine
the standard deviations.

CAT activity was detected by thin-layer chromatographic

separation of [ 14C]-chloramphenicol from its acetylated derivatives followed by
autoradiography. Quantitation was done using a Phosphorimager (Molecular Dynamics).
In vivo labeling and immunoprecipitation. Saos-2 cells were transfected with p53
expression plasmids (or expression vector alone) as indicated. Twenty-four hours post
transfection labeling of cellular proteins was carried out with 35 S-methionine for 2hrs
after which cells were harvested and cell extracts prepared [ 1 88]. Immunoprecipitations
were carried out for 1 4hrs at 4°C using the indicated monoclonal antibodies [ 1 88].
PAb42 1 [263, 264] was used to bind p53 proteins with an intact C-terminus (intact p53D28 1 G as well as p53 del. 1 -293) and DO I [263, 264] was used to detect p53 proteins
with an intact N-terminus (p53-D28 I G but not p53 del. 1 -293).
RNA isolation and microarray hybridization analysis. Total RNA was isolated
from stably transfected 1 0(3) cells using Trizol (Gibco) reagent following manufacturer's
protocol. Quality of the RNAs was checked by 1 .2% agarose TBE gel electrophoresis
[236]. Microarray analysis from RNA from 1 0(3) cells stably transfected with ( 1 ) vector
alone and (2) p53-D2 8 1 G was done by Incyte Genomics, Inc. (Palo Alto, CA) starting
from whole RNA.

Briefly, polyadenylated RNA was isolated with the OligoTex

(Qiagen) RNA kit. Polyadenylated RNA was reverse transcribed to generate Cy3- and
Cy5-labeled cDNA probes, respectively. cDNA probes were competitively hybridized to
a mouse Unigene 1 cDNA microarray (lncyte Genomics, Inc.) containing immobilized
cDNA fragments (average cONA length, 500-5000 base pairs).
fluorescence were imaged

Cy3 and Cy5

individually, and the normalized ratios of Cy3/Cy5
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fluorescence at a given spot on the microarray were used to calculate differential gene
expressIOn.
Quantitative real-time peR.

Relative quantitation of gene expression was

performed using quantitative real-time PCR (QPCR).

The relative amount of each

sample was calculated from a standard curve after employing a Fit Points algorithm.
This expression value was normalized to a housekeeping gene, glyceraldehyde 3phosphate dehydrogenase (GAPDH) [265].

This method is described in detail by

Johnson et al [266] and Tanguay et al. [267]. Following is a brief description of the
entire process.
(a) cDNA synthesis.

Total RNA was isolated from stably transfected 1 0(3) cells

using Trizol reagent (Gibco BRL) following the manufacturer's instructions.

Ten

micrograms of total RNA was treated with RQ I RNAse-free DNase (Promega), followed
by phenol-chloroform extraction and ethanol precipitation. cDNA was synthesized with
random hexamers using the Thermoscript RT-PCR System (Gibco BRL) according to the
manufacturer's protocol.
(b) Primers. Primers were designed using Oligo 5.0 Software (National Biosciences,
Inc) and synthesized by Integrated DNA Technologies. Primer optimization was
performed to determine the optimal concentration of MgCh and annealing temperature
for each primer set.

Relative standard curves were constructed for each target gene.

Serial dilutions were made, and given arbitrary values corresponding to the dilutions.
(c) Quantitative real-time PCR. Quantitative real-time PCR was performed using a
LightCycler (Roche). Each reaction (20111) contained 2111 of the respective diluted cDNA,
primers (0.5IlM), and 4mM MgCh, and FastStart Reaction Mix SYBR Green I, (Roche)
which includes FastStart Taq DNA polymerase, reaction buffer, dNTPs, and SYBR
Green I dye. A negative control was included in each QPCR run .
Except for the composition of the standard curves, each reaction was performed in
triplicate. Samples were investigated with murine GAPDH: 5 ' - CCA GCC TCG TCC
CGT AGA CA -3' and 5 ' - GCC TCA CCC CAT TTG ATG ITA GTG -3', murine
PCNA: 5 ' - GAT AAA GAA GAG GAG GCG GTA A -3' and 5 ' - ACA CGC TGG CAT
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CTC AGG AGC A -3', and murine NF-KB2: S ' - TGG CCC CTA TCT GGT GAT TGT 3' and S ' - ACA CTC CCA ACT CTG AAC ACT GCT -3'. Agarose gel electrophoresis
and melting curve analysis were used to demonstrate the presence of a specific product.
Colony formation assay. t o(3) cells stably transfected with the vector pCMVBam

NEO [2SS] or stably expressing pS3-D28 1 G [ 1 34] each in 1 0cm plates were transfected
with I J.lg of pHyg and S J.lg ( I ) pCMVBam [ 1 88], (2) pCMVBam WTpS3 [ 1 88], (3)
pCMVBam FLAG-p73a [ 1 97], (4) pCMVBam FLAG-p73 � Deb [ 1 97], or (S)
pCMVBam pS3 del. 1 -293 [23] .

Transfections were done by calcium phosphate

precipitation technique as described earlier [ 1 34] . After 48hr of transfection cells were
subcultured 1 :4; hygromycin was added next day at 200 J.lg/ml to start the selection
process. Neomycin (G4 1 8 at 200 J.lg/ml) was also added to those cells selected earlier for
neomycin resistance as described before [ 1 34]. Every 2-3 days media were changed.
After 3 weeks, cells were fixed with methanol and stained by methylene blue.
The tumorigenic potential of 1 0(3) cells expressing pS3
derivatives was tested using nude mice. Cells (S x 1 06 per site) were subcutaneously
Tumorigenicity assay.

injected into flanks of athymic nude mice (National Cancer Institute) and tumor
development was monitored as described [ 1 1 ] ; [ 1 34] .
Immunoprecipitation. In vivo complex formation between pS3-D2 8 1 G and pS3 del.

1 -293 in 1 0(3) cells stably transfected to express pS3-D2 8 1 G and pS3 del. 1 -293 was
done by immunoprecipitation of pS3-D28 1 G with an antibody (DO l ) that recognizes a
motif on the N-terrninal part of the protein that is absent in pS3 del. 1 -293 . Cells from a
1 0 cm dish were harvested in 4 ml of l OS buffer (containing 2S0mM HEPES, pH 7.2,
I .S% NP40, O.S% Triton X- I OO, 0.02S% SDS, SOmM sodium phosphate buffer, pH 7.0,
SmM NaF, O.SmM PMSF and 2.S mM DTI) as described. One ml of the extract was
then incubated with 2J.lg of pS3 antibody DO l and 1 6J.ll of protein A agarose (Invitrogen)
and tilted overnight at 4°C. The following morning, the immunoprecipitate was washed
three times with l OS buffer and once with a buffer containing 1 0mM Tris pH 7.S, SOmM
NaCl, O.S% sodium deoxycholate and O.S% Triton X- t OO.

The pellet was then

suspended in 20 J.ll of 2X Laemmli loading buffer, boiled and analyzed by I S% SDS
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polyacrylamide gel electrophoresis, followed by Western blot analysis using PAb42 1 as
the probe.

Chapter 4 Methods.
Colony formation assay.

1 0(3) cells were plated at a density of 6 x 1 05 cells per

plate in 1 0cm dishes 24 hrs prior to transfection and transfected using the calcium
phosphate method as described earlier [ 1 88, 1 9 1 ] . Cells were transfected with I Jlg of
pCMVBam NEO and 5 Jlg ( I ) pCMVBam [ 1 88, 255], (2) pCMVBam WTp53, (3)
pCMVBam p53-V I 43A, (4) pCMVBam p53-V I 57F, (5) pCMVBam p53-Y I 63C, (6)
pCMVBam p53-R I 75H, (7) pCMVBam p53-H I 79Y, (8) pCMVBam p53-Ll 94R, (9)
pCMVBam p53-R273H, ( 1 0) pCMVBam p53-D28 I G, or ( I I ) pCMVBam p53-R282W.
After 48 hr of transfection cells were subcultured I : 3 ; neomycin (G4 1 8) was added next
day at 200 Jlg/ml to start the selection process. Every 3-4 days the media was changed.
After three weeks, the colonies formed were fixed with methanol and stained with
methylene blue [ 1 9 1 ]. Only colonies containing more than thirty cells were counted.
Purification of pS3.

WTp53 was purified as described [ 1 95].

Recombinant

baculovirus expressing WT was used to infect SF9 cells. The virus was prepared as
described [ 1 95]. The protein was purified by affinity chromatography using a column of
Affigel- I O coupled with the purified monoclonal antibody PAb42 1 [268]. Purity of the
preparation was checked by SDS-PAGE and subsequent analysis by Coomassie [ 1 95].
Electrophoretic Mobility Shift Assay.

Saos-2 cells were transfected using the

calcium phosphate precipitation method [ 1 88] with an expression plasmid containing the
cDNA for the WT or mutant p53 protein as indicated in the figure. After 48hrs, nuclear
extracts were prepared following the method described in Yang et al [269] using a
solution containing 20mM HEPES, pH 7.8; 25% glycerol; 520mM NaCI; 1 .5mM MgCb;
O. l mM EDTA; 0.5mM DTT, 0.5mM PMSF; 2% Nonidet P-40; and protease inhibitor
cocktail I (Calbiochem). The probes used were radiolabeled with [a32P]_dCTP using
Klenow fragment of DNA polymerase I of E.

coli (New England Biolabs).

Approximately I OJlg of total protein [ 1 00ng of purified p53 [ 1 95, 270] in the control gel]
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were incubated at 1 8°C for 30 minutes in binding buffer [4% glycerol, I mM MgCh.
0.5mM EDTA, 0.5mM DTT, 50mM NaC!, 1 0mM Tris-HCL, pH 7.5, and I llg of poly
dI:dC (Pharmacia)] with 5,000 cpm of radiolabeled probe.

For the competition and

supershifting studies, proteins were pre-incubated for 1 5 minutes in binding buffer with
either an excess of unlabeled competitor oligodeoxynucleotide containing a p53-binding
site (P2 1 WT) or a probe containing the same site mutated in two places to prevent
binding of p53 (P2 1 MT). The labeled probes were added after the pre-incubation and the
binding reactions were carried out as described above. The antibody DO I , specific for
detecting p53, was used for supershifting. The extracts were then loaded into a 4%
polyacrylamide gel and separated by electrophoresis at 200 volts at 1 2°C. The gel was
dried and the presence of radioactively labeled DNA was detected by autoradiography.
Probes used: I ) p2 I WT: 5'- GAT TCG TCA GGA ACA TGT CCC AAC ATG TTG
AGC TCT GGA -3' and 5'- AGC TTC CAG AGC TCA ACA TGT TGG GAC ATG
TTC CTG ACG -3'; p2 I MT: 5'-GAT TCG TCA GGA AAA TIT CCC AAA ATT TTG
AGC TCT GGA -3' and 5'- AGC TTC CAG AGC TCA AAA TTT TGG GAA ATT TTC
CTG ACG -3'.
Transfections and luciferase assay. For transient transcriptional promoter assays

human osteosarcoma (Saos-2) cells were cultured and transfected using Lipofectamine
2000 (Invitrogen) in 24-well plates following the manufacturer's protocol. Each well
was transfected with 200ng of the indicated promoter-Iuciferase construct and 25ng
(p2 1 .Luc), 1 00ng (MDM2.Luc), 250ng (ASNS.Luc and hTERT.Luc), or 800ng
(SV 40.Luc) of the p53 expression plasmid. Puc l 8 DNA was used as filler DNA up to
I llg. Cells were harvested 36-48 hours after transfection, and extracts were prepared
using Reporter Lysis Buffer (Promega). Equal amounts of protein from each extract were
used for the luciferase assay. Value of the vector control was set to 1 00 and relative
luciferase activity form the remaining samples calculated. All assays were repeated three
times or more.
5

Growth rate assay. Cells were seeded at a density of I x l 0 cells per 60-mm plate.

Five plates of each cell line were plated initially. Whenever needed one plate of each
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was trypsinized, and cells were suspended in I ml of serum containing medium; cells
were counted each day using a hemocytometer and the total number of cells calculated
and plotted. Media in the remaining plates were changed every day. Standard deviations
were calculated from three independent experiments run simultaneously.
siRNA transfection and cell viability assay. H I 299 cells (3x I 05) expressing pS3R I 7SH (H-RI 7SH-72) or vector alone (HC-S) were transfected by Lipofectamine 2000
with siRNA directed against pS3 or a non-specific sequence (33nM final concentration)
24hrs after plating.

Cells were transfected a second time 24hrs later. Cells were then

plated at equal density (3000 cells per well) 48hrs after the first transfection (Day 2) in
96-well plates.

Cell viability was measured using an MTS assay kit (CeIlTiter® 96

Aqueous Non-Radioactive Cell Proliferation Assay Kit, Promega) for the following five
days following the manufacturer's protocol. Mutant pS3 protein levels were detected
using antibody PAb 1 80 I from a parallel experiment; p-actin (Sigma, AC- I S) was used as
loading control.

Cell viability was expressed as a percentage of HCS control cells

transfected with the same siRNA. siRNA sequences used were: I ) control siRNA ('C'):
S ' - CAU GUC AUG UGU CAC AUC UCT T -3' and S ' - GAG AUG UGA CAC AUG
ACA UGT T -3'

2) pS3 siRNA ('pS3'): S ' - GCA UGA ACC GGA GGC CCA UTT -3'

and S ' - AUG GGC CUC CGG UUC AUG CIT -3' [ 1 98].
Drug sensitivity assays.

H I 299 (or 2 I PT) cells stably expressing pS3-RI 7SH, -

R I 7SH (L22QIW23S), -R273H, -D28 I G, -D28 1 G (L22QIW23S) or transfected with
vector alone (as indicated in the figure), were plated at equal densities and treated with a
final concentration of 3-61lM etoposide (Sigma) for 48hrs as specified in the text.
Chemosensitivity of the cells was then measured by two different methods: ( l ) colony
formation or (2) bromodeoxyuridine (BrdU) incorporation. Colony formation assay:
Cells were plated at (Sx I 04 cellsll 0 cm dish) and exposed to a final concentration of 61lM
etoposide for 48hrs. After treatment, plates were washed and the media replaced. The
surviving cells were allowed to form colonies for 2-3 weeks with periodic changes of
media. Colonies were fixed with methanol, stained with methylene blue and counted as
described earlier [ l S6]. Control plates were plated at Sx I 03 cellsll 0 cm dish and treated
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with an equal amount of DMSO. Control plates were assessed for plating efficiency and
DMSO effects on cell growth. BrdU incorporation assay: Cells were plated at a density
of I x l 06 in a 1 0 cm dish in the presence of etoposide (61lM final concentration) or
DMSO as control for 4S-72h. Cells were incubated in the presence of I OIlM BrdU for 40
minutes. After washing with Dulbecco's Phosphate Buffer Solution (DPBS), cells were
trypsinized, counted, fixed by vigorous vortexing and addition of cold absolute ethanol
(ETOH) drop-wise. Cells were then stored at 4°C for at least I Shrs.

Samples were

washed with DPBS plus O.S% BSA to remove EtOH. Fixed cells were treated with 400
III 2N HCI for 20 minutes, followed by incubation in O. I M sodium borate pH S.S for 2
minutes. Samples were washed and resuspended in DPBS plus O.S% BSA and O.S%
Tween 20 followed by incubation with anti-BrdU antibody coupled with fluorescein
isothiocyanate (FITC) for 1 h in the dark with tilting. After washing to remove excess
antibody, cells were resuspended in propidium iodide staining solution for at least I hr
prior to fluorescence-activated cell sorting (F'ACS) analysis [27 1 , 272]. Samples were
gated for sub-G 1 DNA containing cells.
Soft agar plating efficiency assay. Saos-2 cells expressing mutant pS3-D2S 1 G, the

transactivation deficient pS3-D2 S 1 G (L22QIW23S) or vector alone were plated at a
density of 3000 cells/well over a .S% agar-medium plug. Assays were carried out in 6well plates.

Cells were plated in .2S% agar-medium for 4-S weeks with periodic

additions of growth media. After four weeks, the colonies formed were counted under a
light microscope. Colonies with an apparent cell number >30 were counted. The agar
medium used in the assay contained the appropriate selection agents.

Chapter 5 Methods.
DNA microarray hybridization. Expression profiles of mutant pS3-expressing cells

were compared with H 1 299 cells stably transfected with vector alone.
Cells
6
(approximately 3x 1 0 cells at the time of preparation) were plated 36-40hrs prior to RNA
preparation. To compare to the mutant pS3 expression profiles, H 1 299 cells were also
infected with recombinant adenovirus expressing WTpS3 and compared to cells infected
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with adenovirus expressing p-galactosidase as a control. One culture (approximately
3 x l 06 cells) per microarray sample was used. All microarray hybridization analyses were
performed with biological duplicates of each mutant p53 expressing cell line using
Affymetrix U95Av2 chips by either the GeneChip Core lab at UCSD or Virginia
Commonwealth University' s institutional Nucleic Acid Research Facility. The U95Av2
arrays represent 1 2,625 human gene sequences and expressed sequence tags (ESTs)
previously characterized, in which each gene is represented by a probe set consisting of
1 6-20 probes. The general procedures for microarray hybridization and analysis have
been described elsewhere [273 ] .
Data management and analysis.

Data analysis was done using Affymetrix

Microarray Analysis Suite version 4 (MAS 4).

All arrays were normalized by a

correction to a set value of median total hybridization intensity. Changes in gene
expression were detected in terms of statistical significance of change in expression for a
given gene between two compared microarrays (S-score) [ 1 99, 200). S-score analysis
takes into account signals detected by 1 6-20 multiple probe pairs for individual genes, as
well as intensity-dependent and -independent noise.
described elsewhere [273) .

The general procedures are

Briefly, the normalized files generated by the MAS 4

software were analyzed by the S-score program [ 1 99). Two hybridizations from each cell
line were performed and changes in gene expression were detected in terms of S-score
[ 1 99, 200).

S-scores are derived to have a mean value of zero (representing no change)

with a standard deviation of 1 . Genes with an average intensity difference value of less
than 50 in at least one sample were filtered out, resulting in 1 724 genes. The S-scores
generated from our mutant p53-expressing cell lines were then analyzed for significance
across replicate experiments by using a permutation method performed with the
Significance Analysis of Microarray (SAM) program from Stanford University [20 1 ) .
The settings for this analysis were: one-class response, unlogged data, and 300
permutations, K-nearest neighbor imputer of 1 0 and a random number seed of
1 23456789. Once the program reported the list of ranked genes, the "delta value" was
adjusted to a stringent False Discovery Rate (FDR) of 0.3 %. Cluster analysis was done
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using the Cluster and TreeView programs (http://rana.lbl.govl) to provide a graphical
display of the expression patterns [256, 257] . Genes reported by SAM were analyzed by
hierarchical clustering with average linkage grouping.

For our analysis the arrays

themselves were not clustered. Functional grouping of the identified genes was done by
manual editing of GeneOntology categories obtained through the DAVID annotation tool
(http://david.niaid.nih.gov/david/ease.htm) [25 8].
Quantitative PCR (QPCR). QPCR was conducted using the LightCycier (Roche).

Details of this method are described elsewhere [ 1 56]. Briefly, cDNA was synthesized
using the Thermoscript RT-PCR system (Invitrogen). Primers were designed using Oligo
5 (Molecular Biology Insights) and synthesized by Sigma Genosys.
performed in triplicate utilizing SYBR Green dye.

Reactions were

. The degree of expression was

quantitated using a relative standard curve and normalized to an internal control (BMV)
corresponding to the cDNA batch [ 1 56]. Primer used were: 1 ) Asparagine synthetase
(ASNS): 5' AGA GAT TCT CTG GCG ACC AAA AGA -3 ' and 5 ' - CTG GGT AAT
GGC GIT CAA AGA CIT -3 ' ; 2) A ngiopoietin J (ANGPT l ): 5'- GAT GTC AAT GGG
GGA GGT T -3 ' and 5 ' - CTC TGA CTG GTA ATG GCA AAA ATA -3 ' ; 3) Cyclin B2:
5 ' - CTG CCA CGC ITT ITC TGA TG -3 ' and 5'- GAC TTG TAC CAG CCA ATC
CA -3 ' 4) c-myc: 5 ' - GCC GCC GCC AAG CTC GTC TCA GAG -3' and 5'- GCT GCT
GGT GGT GGG CGG TGT CTC -3 ' ; 5) Asparaginyl-tRNA synthetase (NARS): 5'- GCC
GGA TGA GIT GTG TC -3 ' and 5 ' - ACC CCA AIT AGT TCC CAG AA -3'; 6) RNA
polymerase II, polypeptide E (RNA polII E): 5'- CCC ACC GAC CAG ATC ITT G -3'

and 5'- GAC GAC GTG CTC AGG GAC TC -3 ' ; 7) Cell division cycle 25A (CDC25A):
5'- AAG GCC CAT GAG ACT CIT -3' and 5'- AAA CIT GCC AIT CAA AAC AG 3 ' ; 8) ras homologue gene family member G (rhoGAP): 5'- AGT ACA TCC CCA CCG

TGT TC -3' and 5 ' - GGA CTG GCA ATG GAG AAA C -3 ' ; 9) Apoptosis inhibitor 5
(API5): 5'- CCG ACC TAG AAC AGA CCT T -3 ' and 5 ' - GCC AAC AAT ITC AAT
ACC TC -3'; 1 0) Associated molecule with the SH3 domain ofSTAM (AMSH): 5'- TAG
ATG TGT TCC CAA CCT TA -3 ' and 5'- GIT GGC ACT GGC TAA CTG -3 ' ; 1 1 )
estrogen receptor binding protein site associated antigen 9 (EBAG9): 5'- TGC CIT
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ITA ITC ATC AGT CIT C -3 ' and 5 ' - CGG CTG CTC TCT TIT CTC T -3'; 1 2)
integrin

a6

(lTGA6): 5 ' - GTC CAG AGC CAA GGT CCA G -3 ' and 5 '- CTC AAT

CGC CCA TCA CAA AA -3 ' ; 1 3) minichromosome maintenance protein

6

(MCM6): 5 '

ATC CCT CIT GCC AAG GAT I T -3' and 5 '- GAA AAG ITC CGC TCA CAA GC 3 ' ; 1 4) transcription factor E2F-5 (E2F-5): 5 '- CCC CCA CCT GAT GAC CTC AC -3 '
and 5' - CTG CCG GGG TAG GAG AAA GC -3 ' ; and 1 5) C-Syn proto-oncogene (C
SYN): 5 ' - TGA ACA GCT CGG AAG GA -3' and 5'- CCC AAT CAC GGA TAG AAA
GT -3 ' .
Cloning o f presumptive promoters. Cloning of the presumptive gene promoters

was done using genomic data sequence available in the NCBI database.

Briefly,

sequence specific primers were designed to amplify (by PCR) a genomic DNA fragment
of up to I Kb upstream sequences containing the transcriptional start site for each of the
promoters.

Genomic DNA from MCF-7 cells was extracted using DNAzol reagent

(Invitrogen) and used in the PCR reaction as template. Primers were designed using the
Oligo 5 (Molecular Biology Insight) program. The PCR fragment was then purified and
cloned into the pGL3 Luciferase reporter plasmid (Promega) using the indicated
restriction enzymes. Sequences of the fragment were confirmed by DNA sequencing
(Amplicon Express); clones bearing no base pair mutations were selected for further use.
The following primers sets were use: I ) Angiopoietin I (ANGPT l ): 5 ' - CGG GGT ACC
CAG GAG GIT TIT ATG TGG AA -3' and 5 '- CCC AAG CIT AAT GGC AGC GAG
GAA -3' (KpnI and HindIII); 2) Integrin a6 (lTGA6): 5 '- GGA AGA TCT AGC CIT
CAT GCC ACC TAC AC -3' and 5 '- CCC AAG CIT GCC ACC ITC GCC TCC TC 3 ' (BglII and HindIII); 3) Cyclin B2: 5 ' -CGG GGT ACC TGG GCT GAT TAT TAG
ACG AA -3' and 5' - GGA AGA TCT ACG GGG AAG GCA AGA -3' (KpnJ and BglII);
4) DNA polymerase delta subunit 2 (POLD2): 5'- CGG GGT ACC AGG CCC AGG
GAA GTA GCA GA -3 ' and 5 '- GGA AGA TCT GCC CAC CGA CCC AGG AG -3'
(Kpnl and BglII); 5) Transcription factor E2F-5 (E2F-5): 5 '- CGG GGT ACC ATG AAA
ACC AAC CCT AAA ACT CCA -3' and 5 '- CCC AAG CIT GAT CCA GAA CGC
CGT CCT T -3' (Kpnl and HindIII). Luciferase constructs for the Asparagine synthetase
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and EBAG9 were kind gifts of Michael Kilberg and Satoshi Inoue respectively [2 1 2,
2 1 5] .
Transfection and luciferase Assays.

Luciferase assays were done as described

[ 1 56]. Saos-2 (p53-null human osteosarcoma) cells were plated at equal density 24 hrs
prior to transfection. Culture media was changed on the day of transfection. Cells were
transfected with 1 00ng of the appropriate promoter-luciferase plasmids and 250ng of an
expression plasmid (pCMVBam) for WTp53, p53-RI 75H, -R273H, -D28 1 G -D28 1 G
(L22QIW23S) or vector alone [ 1 56]. Cells were harvested 48hrs after transfection using
Reporter Lysis Buffer (Promega). Luciferase activity was detected using a Luminometer
from Turner Designs. Cell extracts were normalized based on total protein concentration;
the vector reading was arbitrarily set to 1 00. Alternatively, cells were transfected with
increasing concentrations of the expression plasmid for p52-R273H or -D28 l G and
1 00ng of the ASNS promoter-luciferase construct.

Assays were then conducted as

described above.
Adenovirus preparation and infection. A) The p53 (WT or mutant) gene was first

cloned in a plasmid vector downstream of the human cytomegalovirus promoter,
pZEROtg CMV. The viruses were generated by recombination in bacteria as described
[274]. For control, we generated a recombinant adenovirus expressing �-galactosidase
where the �-galactosidase gene is cloned downstream of the CMV promoter. In a 1 0 cm
dish 3x 1 06 H 1 299 cells [26 1 ] were infected with the recombinant adenoviruses
expressing WTp53 , p53-D28 1 G or �-gahictosidase at an MOl of 5 . The infection was
conducted in the absence of serum. Total RNA was harvested at 24 or 48 hours after
adenoviral infection from H 1 299 cells using Trizol (Invitrogen) reagent following
manufacturer's protocol. Quality of the RNAs was checked by 1 .2% agarose Tris-borate
EDTA gel electrophoresis. B) H 1 299 cells were infected with increasing MOIs ( 1 , 5, 1 0
and 20) with a recombinant virus expressing p53-R273H (or �-galactosidase).

Cell

lysates were prepared 48 hrs after infection. Lysates were normalized based on total
protein concentration and resolved by SDS-PAGE.

ASNS was detected using an

antibody specific for the protein (a kind gift from Dr. Michael Kilberg's laboratory).
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Chromatin immunoprecipitation. Chromatin immunoprecipitations were done as

described [2 1 6, 27S, 276]. Briefly, exponentially growing H 1 299 cells expressing mutant
pS3-R273H ( l x l 07) were crosslinked with 1 % formaldehyde for I S minutes and the
reaction stopped by addition of glycine to a final concentration of 0. 1 2SM for I S more
minutes. Cells were collected in and washed once with PBS, once with Wash buffer 1
(0.2S% Triton X- l OO, l OmM EDTA, pH 8, O.S mM EGTA, pH7.S, HEPES, pH 7.S),
once with Wash buffer 2 (0.2M NaCl, I mM EDTA, pH 8, O.SmM EGTA, pH 7.S, 1 0mM
HEPES, pH 7.S) and lysed in SOOIlI of Lysis buffer ( l SOmM NaC!, 2SmM Tris-HCl, pH
7.S, SmM EDTA, pH8, 1 % Triton X- I 00, 0. 1 % SDS, O.S% Sodium Deoxycholate). Cells
were subjected to sonication and the chromatin sonicated to SOO- 1 00bp length fragments.
DNA from approximately 2.Sx 1 06 cells was used in each immunoprecipitation. The
immunoprecipitation volume was increased to I ml by addition of IP buffer (2S0mM
NaC!, 2SmM Tris-HCl, pH 7.S, SmM EDTA, pH 8, 1 % Triton X- I 00, 0. 1 % SDS, 0.5%
Sodium Deoxycholate), precleared with 30 III of protein A agarose (Calbiochem) and the
indicated proteins immunoprecipitated overnight at 4°C with gentle tilting using speci fic
antibody for pS3 or a control antibody (pS3, Oncogene, Ab-6; Normal rabbit IgG, Santa
Cruz) following the manufacturer's recommendations. The antibody was captured the
following day with I S III of SO% slurry protein A agarose with gentle tilting at room
temperature.

The immunoprecipitate was pelleted and washed three times with

Immunoprecipitation buffer, once with a High Salt wash (SOOmM NaCl, SOmM Tris-HCl,
pH 8, 0. 1 % SDS, 1 % NP-40), once with a LiCI wash (800mM LiCl, SOmM Tn s-HCl, pH
8, O.S% Sodium Deoxycholate, 1 % NP-40) and three times with I X TE. The supernatant
from the IgG immunoprecipitation was saved and labeled as input. The antibody-DNA
complexes were eluted with two 200lli washes of Elution buffer (2% SDS, 1 0mM DTT,
1 00mM NaHC03).

The two elution fractions were combined and the crosslinking

reversed by incubation at 6SoC for six hours. Ten nanograms of pGEM(3z)f- were added
to each sample to act as an internal control and the DNA was then ethanol precipitated
overnight. Samples were then dissolved in 1 80lll of I X TE and RNAse ( l Ollg) and
protease K (20llg) treated. Proteins were removed by phenol-chloroform extraction and
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the isolated DNA ethanol precipitated overnight. The immunoprecipitated samples were
dissolved in 1 2J.1l and the input sample in 200J.1l of I X TE. QPCR was carried out as
described above.

The input DNA was diluted approximately 1 : 1 00 prior to PCR.

Relative amounts of PCR product for the genes in this study were normalized to the
relative amounts of the pGEM(3z)f- DNA in that sample and the Antibody/Input ratio
calculated using the normalized amounts. The primers used were: 1 ) ASNS: 5'- AAT
ITA ITT CGG TGC TG -3' and 5 ' - GAA GCC AAA ATA CAT CAG -3' 2)
pGEM(3z)f-: 5'- GTA ATA CGA CTC ACT ATA GGG -3' and 5'- AIT TAG GTG
ACA CTA TAG AAT AC -3'
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P.

Appendices

Appendix A.

The work presented in this appendix has not been published at the present time. It
explores the role of the NF-KB2 gene in decreased chemosensitivity induced by mutant
p53. This work was originally started by Katherine E. R. Stagliano and completed by
myself. Although not directly related to the work in this dissertation, it includes and
supports some of the data presented above. Only the results, figures, figure legends and
methods sections from the manuscript are reproduced here in an edited form.

Appendix B.

During the process of writing this dissertation, new microarray data was generated
using cell lines expressing the transactivation deficient mutant p53-D2 8 1 G (L22Q/W23S)
derived from H 1 299 cells.

Presented here is a more comprehensive analysis of the

microarray data presented above in conjunction with the newly generated data. Included
is also data obtained from analyses of 2 1 PT cells expressing mutant p53-RI 75H, R273H
or -D28 1 G.
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Appendix A.

Tumor-derived pS3 mutants induce NF-KB2 gene expression.

Mariano 1. Scian, Katherine E. R. Stagliano, Michelle A. E. Anderson, Sajida
Hassan ' , Melissa Bowman ' , Mike F. Miles ' , Swati Palit Deb and Sumitra Deb.

Department of Biochemistry and the Massey Cancer Center,
, Department of Pharmacology and Toxicology,
Virginia Commonwealth University, Richmond, VA 23298, USA.

Experimental Results.
8 1 299 and 2 1 PT cells expressing mutant p53 over-express a common set genes,
including NF-KB2, which are inhibited or unaffected by WTp53.

Since data

described earlier suggested that mutant pS3-mediated transactivation is necessary for its
growth promoting functions, microarray hybridization analyses of three H l 299-derived
and three 2 1 PT-derived cell clones expressing pS3 mutants -RI 7SH, -R273H, and D28 1 G were performed. The gene expression profiles of vector transfected H l 299 and
2 1 PT cells were used as controls.

Affymetrix U9SAv2 Arrays (HG-U9SAv2)

representing -1 2,000 sequences were used. Changes in gene expression were detected as
described earlier [ 1 99, 243 ] . A common set of approximately I SO genes was found to be
significantly upregulated by all three pS3 mutants in both the cell lines. Approximately
1 00 of those genes were found to be inhibited or unaffected by WTpS3 but up-regulated
in the presence of mutant pS3. (Table l A shows a partial list). This common set of genes
includes genes involved in cell growth, survival and adhesion (i.e. E2F-S, NF-KB2,
integrin (16, etc.), often implicated in cancer.
This up-regulation was verified by QPCR for a representative group of gene targets
and expression of the triple mutant pS3-D28 1 G (L22Q/W23S) in H l 299 cells did not
result in up-regulation of the same genes [ 1 33] (data not shown). Interestingly, the group
of up-regulated genes includes a member of the NF-KB family, NF-KB2 (P 1 00/pS2),
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which has earlier been shown by our laboratory to be up-regulated in murine 1 0(3) cells
constitutively expressing tumor-derived p53-D28 1 G [ 1 56]. Figure l A (left panel) shows
QPCR analysis demonstrating up-regulation of expression NF-KB2 (P l 00/p52) in
different mutant p53 expressing cell clones.

This up-regulation was also confirmed by

Western blot analysis using a specific antibody against NF-KB2 (P52) in the H 1 299
mutant p53-expressing cell lines (Figure l A; right panel) [ 1 56] . Expression levels ofNF
KB I (P l 05/p50) were also determined by QPCR and found to be unaffected (Figure I A).
NF-KB2 has been implicated in survival and anti-apoptotic functions in cells [208, 209] .
It is possible then, that mutant p53 utilizes the NF-KB2 pathway to reduce drug
sensitivity.
Figure l A. Expression of mutant p53 up-regulates genes in H 1 299 cells.
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Specific NF-KB2 promoters are upregulated by mutant p53 in 9 1 299. NF-KB2

has been shown to have two different promoters ( P I and P2) both of which can be active
in a cell [277]. Using promoter specific primers, PCR using the conditions described by
Lombardi et at [277] with cDNA prepared from H 1 299 cells expressing p53-R 1 75H or
vector control (HC-5) was performed. The data shown in Figure 2A demonstrate that in
H 1 299 cells mutant p53 up-regulates NF-KB2 (P l 00/p52) expression using the P2
promoter, whereas the P I promoter remains unaffected.
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Figure 2A. Mutant p53 up-regulates NF-KB2 using the P2 promoter in H1 299 cells.
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Mutant p53 transactivates the NF-KB2 P2 promoter in vivo.

After ascertaining

that mutant p53 up-regulates the P2 promoter of NF-KB2 (PI OO/p52), the P2 promoter
sequences were cloned upstream of the luciferase gene in pGL3 vector as described in
Materials and Methods using published sequence information [277].
transcriptional assays were carried out in p53-null Saos-2 cells.

Transient

Transcriptional results

shown in Figure 3A-a demonstrate that tumor-derived p53 mutants p53-RI 75H, -R273H
and D28 l G transactivate the NF-KB2 P2 promoter, while WTp53 represses, in agreement
with our in vivo expression data. Furthermore, transfection of cells with mutant p53D28 1 G (L22Q/W23S) did not show up-regulation of the NF-KB2 P2 promoter (Figure
3A-a).
The NF-KB pathway is activated in cells expressing mutant p53. To determine

whether expression of mutant p53 results in activation of the NF-KB pathway, NF-KB
specific transcription was assayed using a synthetic construct containing five NF-KB
binding sites upstream of a TATA box cloned upstream of a luciferase reporter gene
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[278]. If the NF-KB pathway is active, more NF-KB2 should result in higher promoter
activity in cells expressing the p53 mutants.
Figure 3A. Mutant p53 up-regulates NF-KB2 P2 promoter.
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As expected, cells expressing mutant p53-RI 75H, -R273H and -D28 1 G had higher
promoter activity in comparison with the HC-5 (stably transfected with vector alone) cell
line (Figure 3A-b) demonstrating that the NF-KB pathway is more active in cells
expressing mutant p53 and that this activation is dependent on transactivation by turnor
derived p53 mutants. Western Blot analysis showed similar levels of expression of p53
in these cells (Figure 3A-b, right inset). Interestingly, at least one of the mutant p53
target genes,

c-myc,

has also been found to be a target of NF-KB suggesting the
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possibility that mutant p53 may be transactivating

c-myc

through NF-lCB [279].

However, it is also possible that both mutant p53 and NF-lCB independently up-regulate
c-myc

expression. Protein expression levels of ReI A and c-Rel, two other members of

the NF-KB protein family was also examined. Western blot analysis using extracts from
vector control H 1 299 cells (HC-5) and H 1 299 cells expressing mutant p53 show no
appreciable difference at the protein level for either of these proteins (data not shown).
Figure 4A. H1 299 cells expressing mutant p53-R1 75H show increased NF-K8

binding.
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0 1 299 cells expressing mutant p53 show increased NF -KB DNA binding. EMSAs

were performed to determine whether NF-KB binding activity changed in cells expressing
mutant p53 compared to the control cells.

Nuclear extracts from HC-5 control and

mutant p53-R1 75H expressing H 1 299 cells were prepared and binding reactions
performed using double-stranded DNA oligonucleotide probe containing the NF-KB
DNA binding site as described [236, 280, 2 8 1 ] . The experimental data obtained suggest
that there is an increase in DNA binding activity in cells expressing the mutant p53-
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R 1 7SH (Figure 4A, single arrows indicate NF-KB complexes). Antibody supershift using
specific antibodies against pSO or pS2 suggests that the complexes formed contain pSO or
pS2 (double arrow). This supershift is not observed in the presence of antibody alone
(lanes 1 7- 1 9). Thus, data shown so far indicate that mutant pS3 expression leads to an
activation of the NF-KB pathway. In parallel, using a WTpS3 ecdysone (Ponasterone A)
inducible cell line [282], similar DNA binding reactions were carried out. Induction of
WTpS3 resulted in increased DNA binding. Unlike in the case of mutant pS3 expressing
cells, these complexes contained pSO in agreement with the results reported by Bohuslav
et af [283] but not pS2 (compare lanes 1 2- 1 S with 24-27). Sp 1 and pS3 were detected to

determine equal loading of protein and proper WTpS3 induction using specific antibodies
as indicated (data not shown).
Over-expression of NF-KB2 in 9 1299 cells leads to loss of sensitivity to etoposide.

The human NF-KB2 (P l 00/pS2) gene [284] was cloned into pIRESpur03 (Clontech), a bi
cistronic expression vector under the CMV immediate-early promoter where the NF-KB2
gene shares the same promoter with the puromycin resistance gene. Because of the bi
cistronic nature of this cloning vector, most of the puromycin-resistant colonies express
the gene of interest. Using this NF-KB2 expression plasmid and the empty expression
vector pools of H 1 299, cells expressing NF-KB2 (or stably transfected with vector alone)
were generated (Figure SA, right panel).
Figure SA. Expression of NF-KB2 confers H 1 299 cells with a decreased sensitivity to

etoposide.
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Cells were exposed to 6JlM etoposide (final concentration) for 48hrs as before. Over
expression of NF-KB2 in these cells led to an increase in the number of surviving cells
compared to the vector control cell line (Figure SA, left panel).

The data presented

demonstrate that NF-KB2 over-expression in H I 299 cells imparts a lack of sensitivity to
etoposide. That mutant pS3 expression in H I 299 cells leads to induction of NF-KB2
expression as well as lack of sensitivity to etoposide suggests that mutant pS3
desensitizes the cells to etoposide via the NF-KB2 signal transduction pathway.
Figure 6A. siRNA against NF-KB2 increases the sensitivity of cells to etoposide.
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NF-KB2 specific siRNA reduces the level of NF-KB2 in 9 1 299 cells expressing
p53 and inhibits mutant p53-induced lack of sensitivity towards etoposide.

Observations reported in Figures I , 3, S and 7 suggest that mutant pS3 may increase
chemoresistance of cells by inducing over-expression of NF-KB2. We tested this notion
by using siRNA capable of reducing expression of NF-KB2 specifically and determined
whether this would lead to increased etoposide sensitivity in H I 299 cells expressing
mutant pS3 (-R I 7SH). We reasoned that a decrease in NF-KB2 protein levels during the
incubation period with etoposide would increase the sensitivity of the cells to the drug.
Two different siRNAs against NF-KB2 were used. After transfection of siRNA specific
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for NF-KB2, the level of NF-KB2 protein is significantly reduced (Figure 9B).

The

parallel nonspecific siRNA had little or no influence (data not shown).
A reduction in NF-KB2 level led to a reduction in the number of surviving cells
(colonies formed) after etoposide regardless of the p53 status in the cells. The average
number of colonies formed is depicted in the figure. In parallel, cells transfected with the
same siRNAs were plated and treated with vehicle (DMSO) as indicated in Materials and
Methods. Plating efficiency differed by less than 1 0% (data not shown). The siRNA
experimental data corroborates our idea that at least one pathway through which mutant
p53 induces chemoresistance in cancer cells is by up-regulating expression of genes such
as NF-KB2.

Figure Legends.
Figure l Ao Expression of mutant p53 up-regulates genes in 0 1 299 cells. Left:

cDNA from mutant p53 expressing H I 299 cells analyzed by QPCR using gene specific
primers for NF-KB I and NF-KB2 expression. NF-KB2 but not NF-KB I is up-regulated
by mutant p53. Right: Western blot demonstrating up-regulation of NF-kB2 in mutant
p53-expressing H I 299 cell lines and a murine cell line [ l 0(3)] stably transfected to
express mutant p53-D2 8 1 G. Cell extracts were prepared using Reporter Lysis Buffer
(Promega). NF-kB2 was detected using a specific antibody as specified in Materials and
Methods
Figure 2A. Mutant p53 up-regulates NF-KB2 using the P2 promoter in 0 1 299
cells.

Using promoter specific primers, PCR was conducted using the conditions

described by Lombardi et at [277] with cDNA prepared from clones of H I 299 cells
expressing mutant p53-R1 75H (or the vector control cell line HC-5). PCR primers are
designed to detect mRNA products resulting from the two NF-KB2 promoters.

PCR

reactions were performed in duplicate. The data shown demonstrates that in H 1 299 cells
mutant p53 up-regulates NF-KB2 using the P2 promoter, whereas the PI promoter
remains unaffected.
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Figure 3A. Mutant pS3 up-regulates NF-KB2 P2 promoter. a. Saos-2 cells were

transfected with 200ng of pGL3 vector containing the NF-kB2 P2 promoter upstream of
the luciferase reporter gene, 200ng of Renilla luciferase (TK.Renilla.luc) control plasmid
and 600ng of the indicated pS3 expression plasmid. Cells lysates were prepared 48hrs
after transfection and luciferase activity detected using the Dual Luciferase Reporter
Assay System (Promega).

Reporter luciferase readings were normalized based on

TK.Renilla.luc control plasmid readings. Fold induction for pS3-RI 7SH, -R273H and
D28 l G, respectively. b. H 1 299 cells expressing mutant pS3-RI 7SH, -R273H, -D2 8 1 G, D28 1 G (L22QIW23S) or vector alone were transfected with SOOng of a reporter plasmid
containing five NF-KB sites.

Cells were harvested 48hrs after transfection, lysates

prepared and luciferase activity detected. Cell extracts were normalized based on total
protein concentration; the vector reading was arbitrarily set to 1 00. Inset shows western
blot analysis demonstrating similar levels of pS3 expression in the cell lines. Protein
amoUnts were normalized based on total protein concentration.
Figure 4A. 8 1299 cells expressing mutant pS3-R1 7S8 show increased NF-KB

Nuclear extracts of HC-S and H-R 1 7SH were incubated as described in
32
Materials and Methods with a P-labeled probe containing the NF-KB DNA binding site
binding.

sequence.

Competition studies were done using a specific competitor (SC, lanes 4-7)

and a non-specific competitor (NSC, lanes 8-1 1 ) in 20x and 40X molar excess (lanes 47).

The single arrow indicates the DNA complexes containing NF-KB complexes.

Increased NF-KB activity is observed in the presence of mutant pS3 (lanes 2-3, 8- 1 1 ).
The double arrow indicates the supershifted complex in the presence of an antibody
specific for NF-KB I (PSO), NF-KB2 (PS2) or pS3 (lanes 1 2- 1 S , 20-2 1 , 24-29). Equal
amounts of protein were added to each lane.
Figure SA. Expression of NF-KB2 confers 8 1299 cells with a decreased
sensitivity to etoposide. H 1 299 cells stably expressing NF-KB2 were treated with 61lM

etoposide final concentration for 48hrs. After treatment the surviving cells were washed
and allowed to form colonies for three weeks with periodic changes of media. Colonies
were then fixed in methanol, stained and counted. The data shown are representative of
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three independent experiments; colony numbers were adjusted to account for plating
differences based on control plates. Control plates were plated at one-tenth the density
and treated with DMSO. Expression of NF-KB2 protein was checked by western blot
(Right). Actin was used as a loading control.
Figure 6A. siRNA against NF-KB2 increases the sensitivity of cells to etoposide.

H l 299 cells expressing mutant p53-R 1 75H (or the control cell line HC5) were plated at
equal densities in 1 2-well plates. Cells were transfected 24 and 48hrs after plating using
siRNAs against NF-KB2 (or a non-specific control) and plated as described in Materials
and Methods 24hrs after the second transfection.

Cells were then exposed to 6JlM

etoposide (final concentration) or vehicle control (DMSO) for 48hrs. Cells were allowed
to grow and form colonies.

Colonies were then fixed with methanol, stained with

methylene blue and counted. A. Graphical representation of the results. The average
number of colonies formed is depicted in the figure. Plating efficiency differed by less
than 1 0% (data not shown). B. Western blot analysis of cells from a parallel experiment
transfected with siRNAs to evaluate the effectiveness of the RNAi constructs. Actin was
used as a loading control.

Experimental Methods.
Generation of stable cell lines. Stable cell lines were generated after transfection of

p53-null H 1 299 and 21 PT cells with mutant p53 expression plasmids (or expression
vector alone), containing a neomycin resistance gene as described [ 1 34]. The following
p53 mutant cell lines were generated: p53-R I 75H, p53-R273H and p53-D28 l G using
G4 1 8 selection (400 Jlg/ml for H l 299 cells and 500 Jlg/ml for 2 1 PT cells). The p53D28 1 G (L22QIW23 S) clones were only generated in H l 299 cells.

H l 299 cells were

also transfected with pIRES-puro3 vector alone or pIRES-pur03 containing NF-KB2,
p53-R I 75H, p53-R273H, p53-D28 1 G or p53-D28 1 G (L22Q/W23S) cDNA. Cells were
selected with 2.5Jlg/ml of puromycin for two weeks. The resulting colonies were then
pooled and used for further assays. 1 0(3) cell clones were generated earlier at 200 Jlg/ml
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G4 1 8 [ 1 34). Hip53, a wild-type p53 inducible cell line, was generated earlier [282) .
None of the cells lines used in our assays Saos-2, H 1 299, 2 1 PT or 1 0(3) express
detectable p53 [ I I , 1 28, 1 33 , 262).

2 1 PT expresses an N-terminally truncated and

functionally inactive p53 [285).
Recombinant

adenoviruses,

adenoviral

infection

and

RNA

preparation.

Recombinant adenoviruses expressing WTp53 and �-galactosidase were generated by the
laboratory of Dr. Kristoffer Valerie, Massey Cancer Center (Richmond, Va) and by the
lab of Atsushi Miyanohara, UCSD Gene Therapy Program. In a 1 0 cm dish 3x 1 06 cells
were infected with the recombinant adenoviruses expressing either WTp53 or �- .
galactosidase at 1 0 multiplicity of infection (MOI)/cell ratio. At 20 hours, RNA was
extracted for microarray analysis.

Total RNA was isolated using Trizol (Invitrogen)

reagent following the manufacturer' s recommendations and checked by 1 .2% agarose
Tris-borate-EDTA gel electrophoresis.
Drug sensitivity assays.

H I 299 (or 2 I PT) cells stably expressing p53-RI 75H, -

R I 75H (L22Q/W23S), -R273H, -D2 8 1 G, -D28 1 G (L22Q/W23S) or transfected with
vector alone (as indicated in the figure), were plated at equal densities and treated with a
final concentration of 3-6J.lM etoposide (Sigma) for 48hrs as specified in the text.
Chemosensitivity of the cells was then measured in two different ways:

( l ) colony

formation after 2-3 weeks, and (2) bromodeoxyuridine (BrdU) incorporation. Colony
formation assay: Cells were plated at a density of 5x I 04 cells in 1 0cm dishes and
exposed to a final concentration of 6J.lM etoposide for 48hrs. After treatment, plates were
washed and the media replaced. The surviving cells were allowed to form colonies for 24 weeks with periodic changes of media. Colonies were fixed with methanol, stained
with methylene blue and counted as described earlier ( 1 56). Control plates were plated at
a density of 5 x 1 03 cells in 1 0 cm plates and treated with an equal amount of dimethyl
sulfoxide (DMSO).

Control plates were assessed for plating efficiency and DMSO
effects on cell growth. BrdU incorporation assay: Cells were plated at a density of I x I 06
in a I Ocm dish in the presence of etoposide (6J.lM final concentration) or DMSO as
control for 48-72h. Cells were incubated in the presence of 1 0J.lM BrdU for 40 minutes.

97

After washing with Dulbecco's Phosphate Buffer Solution (DPBS), cells were
trypsinized, counted, fixed by vigorous vortexing and addition of cold absolute ethanol
(ETOH) drop-wise. Cells were then stored at 4°C for at least 1 8hrs.

Samples were

washed with DPBS plus 0.5% BSA to remove EtOH. Fixed cells were treated with 400
III 2N HCl for 20 minutes, followed by incubation in 0. 1 M sodium borate pH 8.5 for 2
minutes. Samples were washed and re-suspended in DPBS plus 0.5% BSA and 0.5%
Tween 20 followed by incubation with anti-BrdU antibody coupled with fluorescein
isothiocyanate (FITC) for I h in the dark with tilting. After washing to remove excess
antibody, cells were re-suspended in propidium iodide staining solution for at least I hr
prior to florescence-activated cell sorting (FACS) analysis [27 1 , 272].

Samples were

gated for sub-G 1 DNA containing cells.
siRNA transfection. H I 299 cells expressing mutant p53-R1 75H (or the control cell

line HC-5) were plated at equal densities in 1 2-well plates (3 x 1 0\

Cells were

transfected 24 and 48hrs after plating using siRNA against NF-KB2 (or a non-specific
control). Sequences used were: Control (siControl): 5'- CAU GUC AUG UGU CAC
AUC ACT T -3'and 5 ' - GAG AUG UGA CAC AUG ACA UGT T -3 ', NF-KB2
(siNFkB2 # 1 ): 5 ' - GAC AAG GAA GAG GUG CAG CIT -3 ' and 5'- GCU GCA CCU
CUU CCU UGU CIT -3 ' and NF-KB2 #2 (siNFkB2 #2): 5'- GCC CUG AGU GCC
UGA AUC U -3' and 5 ' - AGA UCC AGG CAC UCA GGG CIT -3'. Twenty-four
hours after the second transfection, cells were trypsinized, counted and plated in 1 0 cm
plates at a density of 5x 1 04 cells per plate (control plates were plated at a density of 5x 1 03
cell per plate).

Cells were then treated with 61lM etoposide (final concentration) or

equivalent vehicle control (DMSO).
weeks.

Cells were allowed to form colonies for 2 to 4

Colonies were then fixed with methanol, stained with methylene blue and

counted as described earlier [ 1 56].
DNA microarray hybridization, data management and analysis.

Expression

profiles of mutant p53-expressing cells were compared with H 1 299 (or 2 1 PT) cells stably
transfected with vector alone. Cells infected with recombinant adenovirus expressing
WTp53 were compared to cells infected with adenovirus expressing �-galactosidase as a
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control. All mlcroarray hybridization analyses were performed In duplicate using
Affymetrix U95Av2 chips by either the GeneChip Core lab at UCSD or Virginia
Commonwealth University' s Institutional Nucleic Acid Research facility. U95Av2 Array
represents -1 2,000 human gene sequences that have been previously characterized. The
general procedures for microarray hybridization and analysis are described elsewhere
[273] . Data analysis was done using Affymetrix Microarray Analysis Suite 5 (MAS 5).
Changes in gene expression were detected in terms of statistical significance (S-score) of
change in expression for a given gene between two compared microarrays. S-score
analysis takes into account signals detected by 1 6 multiple probe pairs for individual
genes, as well as intensity-dependent and -independent noise [ 1 99]. Briefly, the files
generated by the Affymetrix software were first filtered to eliminate genes with an
average intensity value less than 50 in at least one of the samples, resulting in 24 1 7 genes
for further study. The filtered data was then analyzed with the S-score program. S-scores
are derived to have a mean value of zero (representing no change) with a standard
deviation of I .

The S-scores generated were then analyzed for significance across

replicate experiments by using a permutation method performed with the significance
analysis of microarray (SAM) program from Stanford University [20 I ] . The settings for
this analysis were: unlogged data, 300 permutations, K-nearest neighbor imputer of 1 0
and a random number seed o f 1 23456789. Once the program reported the list o f ranked
genes, the "delta value" was adjusted to a stringent False Discovery Rate (FDR) of 0.3%
resulting in the identification of 1 49 genes upregulated by all three p53 mutants in both
cell lines.

Clustering analysis was done using the Cluster and TreeView programs

(http://rana.lbl.govl) to provide a graphical display of the expression patterns [256].
Genes reported by SAM were analyzed by hierarchical clustering with average linkage
grouping. For our analysis the arrays were not clustered. Functional grouping of the
identified genes was done by manual editing of Gene Ontology categories obtained
through the DAVID annotation tool (http://david.niaid.nih.gov/davidlease.htm) [25 8].
Quantitative peR.

QPCR was conducted using the LightCycler (Roche) as

described [286]. cDNA was synthesized using the Thermoscript RT-PCR system
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(Invitrogen). Primers were designed using Oligo 5 (Molecular Biology Insights) and
synthesized by Sigma Genosys. Reactions were performed in triplicate utilizing SYBR
Green dye, which exhibits a higher fluorescence upon binding of double-stranded DNA.
The QPCR primers used were, NF- KB2: 5 ' - GGG GCA TCA AAC CTG AAG AIT TCT
-3' and 5 ' - TCC GGA ACA CAA TGG CAT ACT GT -3'; NF-KBl : 5'- CAC ITA GCA
ATC ATC CAC CIT -3' and 5 ' - AGC CCT CAG CAA ATC CT -3'.
NF-KB2 Promoter PCR.

NF-KB2 promoter PCR was performed using the

conditions described by Lombardi et at. [277] with cDNA prepared form H I 299 cells
expressing mutant p53 (or the control cell line HC-5). The promoter specific primers
used were: P I : 5 ' - AGA GCA GCA GCT GCA CAC AG -3 ' and 5'- GCT CTG TCT
AGT GGC TCC -3 ' ; P2: 5 ' - AAC TCC GGA TCT CGC TCT CC -3' and 5'- GCT CTG
TCT AGT GGC TCC -3'. Note that the reverse primer for the P I and P2 promoters is
the same; while the forward primer is different, thus generating two distinct PCR
products of 1 53 bp (P I ) and 1 1 6 bp (P2).
Cloning of presumptive promoter. The presumptive promoter 2 (P2) sequence of

NF-kB2 was cloned in the pGL3 basic vector upstream of the luciferase gene using the
available genomic sequences in the NCBI database and genomic PCR using a
commercial kit (Invitrogen). The primers used were: 5'- CGC TAG CAA CTC GCG
CCT GGT GTC CGT -3' and 5 ' - CCA AGC TTG CGG CAT GAC TCA CTG GGT
TGT AG -3' (forming NheI and BglI I sites at the ends, respectively). The restriction
enzymes in parenthesis indicate the location of the insert in the multiple cloning site of
the pGL3 reporter vector. The P2 promoter was cloned using Saos-2 cells, and contains a
single mismatch (A to G). We found the same mismatch in multiple analyzed clones and
did not investigate any further.

It should be noted though, that an analysis with the

program TFSEARCH (http://www.cbrc.jp/researchidbITFSEARCH.html) indicates that
the sequence does not fall on any known transcription factor-binding site (not shown).
Transient transcriptional assays. Promoters were tested by transient transcriptional

assays using p53-null Saos-2 (human osteosarcoma) cells. Transfections and luciferase
assays were carried out as described [ 1 56]. Saos-2 cells were plated at equal densities in
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24-well plates and transfected with 200 ng of the promoter luciferase construct, 200 ng of
Renilla luciferase control (TK Renilla.luc, used for normalization of transfection) and
500 ng of the corresponding p53 expression plasmid 24hrs after plating. H I 299 cells
stably expressing mutant p53 were plated at a density of 3x I 05 cells/well in 6-well plates
and transfected with 500 ng of a reporter plasmid containing NF-KB sites upstream of the
luciferase gene (kind gift from Dr. Valentine Andela of the University of Rochester)
[278]. Transfections were carried out using the Lipofectamine 2000 reagent (Invitrogen)
following the manufacturer's recommendations. Cell lysates were prepared 48hrs after
transfection using Reporter Lysis Buffer (Promega).

Luciferase activity was detected

using a Luminometer from Turner Designs. Transcriptional assays were repeated at least
three times.
Electrophoretic mobility shift assay (EMSA). Nuclear extracts were prepared in the

following manner. Cells grown to confluency were washed twice in PBS and lyzed in
700 �l of Di griam buffer [28 1 ] [ 1 0 mM HEPES pH 7.9, 1 .5 mM MgCh, 1 0 mM KCI, 0.5
mM DTT, 1 % Nonidet P-40, 0.5 mM PMSF, plus protease inhibitor (cocktail III from

Calbiochem)] by adding the buffer directly onto the plate and incubating on ice for 20
minutes. Cells were then scraped and transferred into a pre-chilled eppendorf tube and
further incubated on ice for 20 minutes. Nuclei were then pelleted at 4000 rpm, 4°C for
1 0 minutes, the supernatant (cytoplasmic extract) stored at -80°C.

The nuclei were

resuspended in 1 00 �I Nuclear extraction buffer [(20 mM HEPES pH 7.9, 25% glycerol,
1 .5 mM MgCh, 0.5 mM DTT, 0. 1 mM EDTA, 1% Nonidet P-40, plus protease
inhibitors] and incubated on ice for I hour. The samples were pelleted at 1 0,000 rpm,
4°C for 1 0 minutes and the supernatant (nuclear extract) stored at -80°C.

Protein

concentrations were determined using Biorad's Protein assay reagent and equal amounts
of protein were used in each binding reaction.

EMSAs were performed as described

[283] using 1 5�g of nuclear extract protein per binding reaction. Reactions were pre
incubated at 25°C for 20 minutes prior to the addition of the oligonucleotide probe. After
pre-incubation, approximately 20,000 counts of labeled probe were added to each
reaction tube and incubated at 25°C for an additional 20 minutes.

For the supershift
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experiments, antibodies ( l Jlg) were added after incubation with the probe and incubated
for an additional 1 5 minutes. Samples were then loaded and complexes separated on a
6%, 0.5X Tris-Borate-EDTA gel run at 200volts for approximately 1 .5-2hrs. The gel was
then fixed, dried and exposed to film. Probes were annealed and 32 p_dCTP labeled using
Klenow fragment as described [236). The oligonucleotide sequences used were: Wild
type (WT) 5' - GAT CCG AGG GCT GGG GAT TCC CAT CTC CCA CGT TIC ACT
TCA -3 ' and 5' - AGC TIG AAG TGA AAC GTG GGA GAT GGG AAT CCC CAG
CCC TCG -3'; Mutant (MT) 5 ' - GAT CCG AGG GCT TTT TAT GAA AAT CTC CCA
CGT TIC ACT TCA -3' and 5 ' - AGC TIG AAG TGA AAC GTG GGA GAT TTT
CAT AAA AAG CCC TCG -3 ' . For competition studies an unlabeled WT probe was use
as the specific competitor (SC) and the MT probe as the non-specific competitor (NSC) at
20X and 40X molar excess. Hip53 cells were induced with 1 0JlM Ponasterone A. NF
KB 1 (P50), NF-KB2 (P52) and p53 specific antibodies were used for the supershift
experiment (Santa Cruz, sc- 1 1 4X; Rockland, cat# 4 1 85 ; Oncogene, Ab-6, respectively).
Western blotting. NF-KB2 and Spl levels were detected using antibodies from

Santa Cruz Biotechnologies (sc-7386 and sc-59 respectively). Actin levels were detected
using an antibody from Sigma (AC - 1 5). NF-kB l (P 1 05/p50), Rei A and c-Rel were
detected using an antibody kit from Calbiochem (cat# ASK20). p53 was detected using
the p53 antibody PAb 1 80 1 . Western blots were developed by the ECL method
(Amersham). In western blots for the siRNA and colony forming assay the H-IRES NF
KB2 (P1 00/p52) cell line, NF-KB2 protein was detected using an antibody from Upstate
Biosciences (cat # 05-36 1 ).
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Appendix B.

The microarray data generated was analyzed as before [236, 243]. S-cores generated
by comparing hybridization signals from mutant p53 expressing cell lines and the
corresponding controlled were analyzed for significance across replicates. The data were
analyzed using the following SAM settings: multiclass analysis, 300 permutations, K
nearest neighbors imputer of 1 0, and a random seed number of 1 23456789. This type of
analysis identifies genes that are differentially regulated between groups of data. In this
case, data from H I 299 cells expressing mutant p53 was labeled as group I ; data from
2 1 PT cells was labeled as group 2; and data from cells expressing the transactivation
deficient p53-D28 1 G (L22Q/W23S) was group 3. The FDR was set to 0.025%. The
Cluster and Tree View programs were used to generate a visual representation of the
results.
There are several, striking features to this figure regarding the modulation of gene
expression by mutant p53 in H I 299 and 2 1 PT cells. First, a larger number of genes is
up-regulated by mutant p53 rather than down-regulated. This suggests that up-regulation
of genes by mutant p53 may play a significantly more important role than down
regulation of genes in mutant p53 oncogenicity.

Second, genes up-regulated in the

H I 299 cells by the transactivating forms of mutant p53 are repressed (Cluster I ) or
unaffected

(Clusters

3)

by

the

transactivation

deficient

mutant

p53-D2 8 1 G

(L22/QIW23S).
Thirdly, a number of genes are up-regulated by the mutant proteins regardless of their
transactivation status (Cluster 3). This suggests that perhaps some transcriptional up
regulation may be due to factors other than the transactivation ability of mutant p53, such
as protein-protein interactions. Also, it appears that genes repressed in H 1 299 cells are
up-regulated by the transactivation deficient form of p53-D2 8 1 G (Box 2). The reasons
for this are unknown.

Perhaps, in order to induce repression of genes, mutant p53

requires an interaction with another factor. The two additional mutations, which disrupt
TAF interactions and c-terminal modifications, may be involved in this interaction. In
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short, mutating these two residues may prevent or disrupt the interaction between mutant
p53 and this second factor resulting in up-regulation of genes rather than repression.
Finally, it is clear from the figure that although mutant p53 up-regulates a number of
genes in H 1 299 cells, this is not the case when the mutant protein is expressed in 2 1 PT
cells (Box 1 ). This is most likely due to the level of stringency used during the analysis.
A less stringent analysis reveals a larger number of genes similarly regulated in both
2 1 PT and H 1 299 cells (data not shown). Nonetheless, it is evident that expression of
mutant p53 in H 1 299 does not lead to a similar transcriptional regulation of genes in
H 1 299 and 2 l PT cells. Perhaps mutant p53 regulation of genes is partially dependent on
the genetic background of the cells.
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